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Abstract 
Epigenetics is subjected to a pressing attention from the scientific community, because 
of its potential to explain the mechanisms of gene activation or repression. In this thesis 
I present a discovery-driven project aimed to the investigation of the epigenetic role in 
human myogenesis (and in particular the differentiation of myoblasts in myotubes). 
Studying epigenetics still presents significant hurdles, both experimental and 
computational. Therefore my first task was the establishment of robust protocols for 
investigating the role of epigenetics players during skeletal muscle differentiation. In 
particular, I focused on setting up the tools for studying DNA methylation and protein-
DNA interactions, through bisulfite sequencing and chromatin immunoprecipitation. In 
this thesis, together with the description of the protocols that I developed, I report the 
first results that were obtained on myogenic cells. 
 
DNA methylation was investigated with bisulfite treatment of the DNA coupled with next 
generation sequencing. A novel method for studying the whole methylome was 
conceived and applied on one myoblast sample using SOLiD 5500xl platform giving 
reliable results. 
However, since the cost of methylome sequencing is still very high, instead of 
producing data for the whole methylome, I decided to focus on selected regions that 
could be relevant in methylation studies. For this reason I used the SureSelect 
MethylSeq Target Enrichment kit (Agilent) that effectively captures more than 2,700,000 
CpG sites in the human genome. 
 
We identified less than 600 differentially methylated sites (DMS) in myoblasts compared 
to myotubes, however we observed that the activation of muscle specific genes seem 
to be poorly correlated with DNA methylation changes. Therefore, we argue that DNA 
methylation does not show a major role in the control of muscle specific genes. 
Interestingly, further analysis revealed that a high percentage of differentially methylated 
regions (DMR) localizes near novel non-coding RNA genes. On the one hand, this 
observation suggests a role for novel regulatory RNAs in the epigenetics of muscle 
differentiation; on the other hand, DNA methylation might have a role in the regulation of 
these RNAs. 
 
Together with DNA methylation, chromatin compaction is a major epigenetics player. In 
order to describe the epigenetic landscape of muscle differentiation, I optimized the 
ChIP-seq approach to define the localization of specific histone modifications on DNA. 
After setting-up the protocol for ChIP-seq, H3K4me3, H3K27me3 and H3K9ac histone 
modifications were mapped on myoblast DNA. As I started integrating gene expression 
and ChIP-seq data, I verified that a great concordance exists between gene expression 
and ChIP-seq results. In particular, euchromatin-associated histone modifications are 
found in transcription start sites of active genes, and heterochromatic signature spans 
promoters and bodies of inactive genes. Further investigation show that genes for non-
coding RNAs have an euchromatic signature. This observation, together with the 
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findings of DMRs in novel non-coding RNA genes, endorses the hypothesis of a role for 
novel regulatory RNAs in myogenic differentiation. 
 
In conclusion, the integration of BS-seq, ChIP-seq and RNA-seq data are opening 
interesting scenarios concerning the involvement of regulatory RNAs, while recent 
reports are suggesting to extend our investigation even to DNA hydroxymethylation in 
the epigenetics of muscle differentiation. 
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Riassunto del lavoro svolto 
Negli ultimi anni l’epigenetica ha raccolto un sempre crescente interesse da parte della 
comunità scientifica, grazie al suo potenziale di spiegare i meccanismi di attivazione e 
repressione dell’espressione genica. In questa tesi si presentano i risultati di un progetto 
di analisi del ruolo dell’epigenetica nella miogenesi umana, mediante approcci genomici. 
Gli studi di epigenetica presentano tuttora ostacoli significativi, sia dal punto di vista 
sperimentale che di analisi computazionale del dato prodotto. Il mio primo obiettivo è 
stato quindi la messa a punto di un protocolli robusti per l’analisi del ruolo dei 
meccanismi epigenetici durante il differenziamento del muscolo scheletrico, in 
particolare la metilazione del DNA e le interazioni DNA-proteine (mediante il 
sequenziamento di DNA trattato con bisulfito e immunoprecipitazione della cromatina). 
In questa tesi, oltre alla descrizione dei protocolli sviluppati, sono riportati i primi risultati 
ottenuti applicando i suddetti protocolli alle cellule miogeniche. 
 
La metilazione è stata analizzata mediante trattamento con bisulfito del DNA, 
sequenziato successivamente con tecniche di nuova generazione (NGS). A tal riguardo 
è stato messo a punto un nuovo metodo per lo studio del metiloma intero, che è stato 
applicato ad un campione di mioblasti e successivamente sequenziato con la 
piattaforma SOLiD 5500xl. 
Questo approccio richiede tuttavia una quantità massiva di sequenze, che ad oggi 
risultano ancora eccessivamente costose. È stato quindi affiancato allo studio del 
metiloma il sequenziamento delle regioni più comunemente analizzate in studi di 
metilazione (ovvero regioni promotoriali ed isole CpG) con un kit di arricchimento di 
regioni target che cattura selettivamente più di 2.700.000 siti CpG nel genoma umano. 
Con questo approccio sono stati identificati meno di 600 siti differenzialmente metilati 
(DMS) nei mioblasti confrontati con i miotubi. Questo studio ha permesso di osservare 
che l’attivazione di geni muscolari sembra poco correlata con cambiamenti nella 
metilazione del DNA, permettendo di ipotizzare che la metilazione del DNA non abbia 
un ruolo centrale nel controllo dell’attivazione dei geni muscolo-specifici. 
L’analisi di questi dati ha inoltre permesso di rilevare che una significativa frazione di 
regioni differenzialmente metilate (DMR) localizza in prossimità di geni codificanti non-
coding RNA. Da un lato quest’osservazione suggerisce che gli RNA regolatori 
potrebber avere un ruolo nell’epigenetica nel differenziamento muscolare, e inoltre che 
la metilazione del DNA potrebbe avere un ruolo nella regolazione di questi RNA. 
 
Un altro aspetto importante della regolazione epigenetica, oltre alla metilazione del 
DNA, è lo stato di condensazione della cromatina. Per vagliarne il contributo nell’ambito 
del differenziamento muscolare, è stato ottimizzato un approccio di 
immunoprecipitazione della cromatina seguito dal sequenziamento (ChIP-Seq) per 
definire la localizzazione nel DNA di specifiche modificazioni istoniche: H3K4me3, 
H3K27me3 and H3K9ac. 
I risultati di questi esperimenti di ChIP-Seq sono stati confrontati con quelli di analisi del 
profilo di espressione (RNA-Seq), permettendo di verificare un ampio margine di 
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sovrapposizione fra il livello di espressione ed i risultati di ChIP-Seq. In particolare le 
modificazioni istoniche associate all’eucromatina localizzano nei pressi del sito di inizio 
di trascrizione di geni espressi, mentre i marker di eterocromatina fiancheggiano i 
promotori dei geni non attivi. Questa osservazione, assieme all’osservazione di DMR in 
nuovi RNA non codificanti, supporta l’ipotesi di un ruolo per nuovi circuiti regolatori di 
RNA nella differenziazione miogenica. 
 
Per concludere, l’integrazione dei dati di BS-Seq, ChIP-Seq e RNA-Seq apre 
interessanti scenari riguardo il ruolo di RNA regolatori. La letteratura più recente 
suggerisce inoltre di estendere le nostre analisi anche all’idrossimetilazione del DNA per 
comprendere appieno il ruolo delle modificazioni epigenetiche nel differenziamento 
muscolare. 
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Introduction 
During my PhD experience I focused on both setting-up the tools to study epigenetics 
and applying these techniques on human myogenic cells. In order to investigate the 
epigenetic changes during adult myogenesis, which is the process of building functional 
muscle from satellite cells, I developed and used ChIP-seq and BS-seq techniques. 
Coupling chromatin immunoprecipitation and bisulfite DNA treatment with next 
generation sequencing permits to investigate at high resolution the genome-wide 
distribution of epigenetic players, both histone modifications and DNA methylation. 
Epigenetics: non-genetics factors determine cell identity 
There are more than 200 cell types in human body, each containing the same DNA 
sequence, but showing different phenotypes and functions. Cell identity is determined 
by the quality and quantity of genes that it expresses and the mechanisms by which 
cells establish, maintain and transmit gene expression profiles to progeny are referred 
to as epigenetic mechanisms and memory. Epigenetics is the study of heritable 
changes in gene expression that cannot be explained by changes in DNA sequence, 
and unravelling the basis of epigenetics is a current challenge in modern biology 
(Hemberger M et al., 2009). 
Transcription factors play a crucial role in the definition of cell identity by determining the 
lineage-specific gene expression profile of a cell, but they are not the only players. In 
fact, their accessibility to DNA is influenced by chromatin compaction that is in turn 
determined by epigenetic mechanisms such as DNA methylation, chromatin modifiers 
enzymes, noncoding RNAs, histone variants and histone modifications (Murrell A et al., 
2005; Guttman M et al., 2009; Henikoff S, 2008; Klose RJ and Bird AP, 2006; Rando 
OJ and Chang HY, 2009). 
C.H. Waddington defined the epigenetic landscape as the “interactions of genes with 
their environment, which bring phenotype into being”. Environmental factors can alter 
the epigenetic state of a cell, allowing the cell to respond and adapt to the environment 
with a rapid and stable modification in gene expression (Bjornsson HT et al., 2008), and 
epigenetics alterations last through multiple cell generations. 
There are two major known epigenetic mechanisms: cytosine methylation in cytosine-
guanine dinucleotide (CpG) in the DNA, and histone modifications, especially acetylation 
and methylation. 
CpG DNA methylation, when happening in CpG-rich promoter regions (CpG islands) 
represses gene transcription (Ribel-Madsen R et al., 2012), while histone modifications 
may result in both activation and silencing of genes (Cheung V et al., 2000). 
Chromatin: functional DNA packaging 
In eukaryote cells, DNA is not naked in the nucleus, but it is wrapped in nucleosomes 
and hierarchically packed in highly ordered structures that constitute the chromatin. The 
nucleosome is the primary chromatin compaction structure and is composed of 147bp 
of DNA wrapped around an octamer of histones (two dimers H2A-H2B, and a tetramer 
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H3-H4) that are basic proteins with a globular core and a protruding N-terminal histone 
tail. Nucleosomes are bonded together by the linker histone H1.  
Chromatin compaction influences transcription factors accessibility to the DNA, thus 
affecting gene expression through epigenetic phenomena such as DNA methylation, 
covalent histone modifications, incorporation of histone variants, nucleosome 
remodelling, and noncoding RNAs (Sharma S et al., 2010). The accessibility of 
transcription machinery to promoters is influenced by nucleosome occupancy (Li B et 
al., 2007) and transcription is allowed only when DNA-histone interactions are weak 
(Baar K, 2010). 
Histone modifications: actors and promoters for chromatin structure 
Post-translational modifications (PTMs) of amino acids in the N-terminal tail of histones 
can modify chromatin condensation, thus influencing the accessibility of DNA to the 
transcriptional machinery. Histone PTMs can directly affect chromatin structure due to 
their chemical properties or can recruit co-factors that in turn modify chromatin 
compaction and accessibility (Kouzarides T, 2007). Spatial and combinatorial relations 
exist between different histone modifications and, by examining the distribution of many 
types of histone modifications along the genome, an association emerges between 
specific genomic features and distinct types of chromatin signature (Barski A et al., 
2007; Mikkelsen TS et al., 2007).  
Histone PTMs can occur on all histones and consist mainly of acetylation and 
methylation, but even phosphorylation, ubiquitination, and sumoylation. 
Histone acetylation is associated with euchromatin 
Enzymatic acetylation of lysine residues is the most common PTM of histones and has 
the effect of neutralizing the positive charge of the lysine amino group. This decreased 
affinity between the histone tail and the negatively charged DNA results in the opening 
of the chromatin structure that becomes transcriptionally active (euchromatin). 
Deacetylation reverses this process, by closing chromatin structure and blocking 
transcription (heterochromatin). Acetyl-lysine residues may also regulate protein-protein 
interactions by acting as docking sites for other co-factors that further activate 
transcription (Alamdari N et al., 2013). 
Histone methylation as docking site for chromatin modifiers 
The enzymatic methylation of lysine or arginine residues in the N-terminal histone tails 
does not modify the amino acids charge and so it is unlikely to alter chromatin 
compaction. This epigenetic modification associates either with euchromatic or 
heterochromatic regions, depending either on the recruited proteins or on the position 
of the histone modification within a genetic region. 
Lysine and arginine can respectively accept up to three and two methyl-groups, and 
effector proteins can recognize mono-, di-, and trimethylated epitopes with different 
affinities so that the degrees of histone methylation influence gene expression. For 
example, trimethylated H3K9 is exclusively associated with silenced genes whereas 
monomethylated H3K9 has been associated with both expressed and repressed 
genes. 
On the other hand, the position of the histone methylation in a genomic region is 
important in determining its effect on gene transcription: for example, for the same 
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gene, H3K9 methylation correlates with transcription if it is in the coding region of a 
gene, but with silencing if it is in the promoter. 
ChIP-seq 
DNA-binding proteins, both transcription factors and histone proteins, play crucial roles 
in cellular processes, such as transcription, splicing, replication and DNA repair. Their 
interactions with DNA can be studied using a technique called ChIP-seq (Furey TS, 
2012). 
Chromatin immunoprecipitation coupled with NGS allow mapping multiple modifications 
in an unbiased fashion and therefore it is the most widely used technique to identify 
genome-wide binding patterns of proteins of interest (transcription factors, histone 
variants, histone modifications, RNA Pol II) (Valouev A et al., 2008; Kharchenko PV et 
al., 2008). 
ChIP is the most direct way to identify the binding sites of a single DNA-binding protein 
or the location of modified histones. In principle, ChIP is based on the selective isolation 
of a chromatin fraction containing a specific antigen. Typically, antibodies that recognize 
a protein of interest are used to “capture” the protein coupled with its associated 
genomic DNA. Determining the sequence of the co-immunoprecipitated DNA permits 
to identify the positions where the protein was bound in the genome. After isolating the 
DNA from the immunoprecipitated chromatin fraction, it is directly sequenced and the 
reads are mapped to a reference genome. The mapping of reads mapping on a specific 
genomic location is directly proportional with the probability of the DNA-protein 
association in that region. 
 
Table 1| Representative sudies in which ChIP-seq was used to analyse the interaction between proteins 
and nucleic acids. 
Transcription factor mapping Johnson DS et al. Science 2007 
Histone mapping Barski A et al. Cell 2007 
Enhancer identification Visel A et al. Nature 2009 
Study DNA methylation Bock C et al. Nat. Biotechnol. 2010 
Study protein-RNA interactions Sanford JR et al. Genome Res. 2009 
ChIP-seq can be used to map transcription factors DNA-binding sites or for analysing 
histone modifications; some examples of the first studies unravelling the potentiality of 
this technique are included in Table 1. 
 
ChIP is the ideal method for learning how a specific protein interacts with the genome in 
its “natural” state and allows the analysis of chromatin dynamic changes during 
physiological perturbation or cellular differentiation. 
The work of the ENCODE consortium (The ENCODE project consortium, 2012) in ChIP-
seq experiments, gave to the scientific community both an enormous amount of 
epigenetic data and a set of guidelines for successfully performing further ChIP-seq 
experiments. The success of this approach largely depends on the optimization of good 
protocols and validation of highly specific antibodies, because antibody quality is 
sometimes variable and unpredictable (Egelhofer TA et al., 2011), also because multiple 
histone modifications can alter the efficacy of certain antibodies (Fuchs SM et al., 2011). 
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There are two general procedures for ChIP experiments: native ChIP (nChIP) and cross-
linking ChIP (XChIP). The most appropriate procedure depends on experimental aims 
and starting material. 
In crosslinking ChIP, formaldehyde is typically used to cross-link proteins to the DNA, 
so a broad range of chromatin-associated factors can be analysed. After formaldehyde 
treatment, chromatin is randomly fragmented by sonication, and the protein of interest 
is immunoprecipitated using a specific antibody. Crosslinks are then reversed and the 
associated DNA purified and sequenced. 
In this ChIP experiment, the substrate is native chromatin (proteins are not cross-linked 
to the DNA) and fragmentation is achieved by micrococcal nuclease digestion. N-ChIP 
applications are suitable for studying proteins that are very tightly associated with 
chromatin, typically histones and their modifications (O’Neill and Turner, 2003). 
DNA methylation 
DNA methylation consists in the enzymatic addition of a methyl group to the 5N 
position of the cytosine, mainly in CpG dinucleotide of CpG islands, but recent evidence 
showed that one quarter of methylated cytosines occurs in non-CpG sites in human 
embryonic stem cells, particularly in gene bodies (Lister R et al., 2009; Bernstein BE et 
al., 2007; Bird AP, 1986). 
Cytosine methylation of the DNA was the first epigenetic mark discovered in human and 
has a role in regulating, especially in suppressing, gene expression, and in silencing 
transposons and repetitive sequences (Beck S et al., 2008, Gibney ER et al., 2010). 
About 70-80% of human CpG dinucleotides are methylated in the human genome, 
especially in the repetitive regions, but 88% of active promoters are associated with 
unmethylated CpGs.  
In mammals DNA methylation is involved in physiological processes such as 
embryogenesis, genomic imprinting and X inactivation (Bestor TH, 2000; Bird A, 2002; 
Lippman Z et al., 2004; Rhee I et al., 2002), and abnormal DNA methylation affects 
human health leading to, for example, chromosomal instability, loss of imprinting and 
tumorigenesis (Feinberg AP, 2007). 
The relationship between gene-promoter hypermethylation and transcriptional 
inactivation has been described, but the mechanisms through which DNA methylation 
regulates genome function are still unclear (Murrel A et al., 2005; Jaenisch R et al., 
2003). 
BS-seq to decipher DNA methylation 
Among the methods to study epigenetics, reviewed in Laird PW, (Laird PW, 2010), BS-
seq was the one chosen for this project. Investigating the role of DNA methylation in 
biological process at genome-wide level requires accurate and sensitive methods and 
to date there are a few techniques, different in cost, resolution and throughput. The 
gold standard to study DNA methylation at single-base resolution is bisulfite 
sequencing, as sodium bisulfite DNA treatment converts unmethylated cytosines to 
uracils and leaves methylated Cs unchanged (Frommer M et al., 1992). It allows 
genome-wide single-base resolution by mapping the bisulfite-converted sequenced 
reads to an in silico converted reference sequence (Cokus SJ et al., 2008; Meissner A 
et al., 2008). 
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There are both enrichment-based and whole-genome approaches for BS-seq. To study 
the entire methylome, a whole genome resequencing is performed after bisulfite 
treatment and, except for repetitive regions; this technique can virtually determine the 
methylation state of the all cytosines in the genome. The first single-base resolution 
whole methylome was published in 2009 and was performed on the genome of 
Arabidopsis thaliana (Lister R et al., 2008; Lister R et al., 2009). 
Sequencing capacities and costs for whole methylome analyses are still high, so BS-
seq studies are often limited to parts of the genome. Among these methods, reduced 
representation bisulfite sequencing (RRBS) is the most widely used (Gu H. et al., 2010) 
and interrogates approximately 10% of the genome.  
I used another enrichment system in which regions of interest are captured by 
hybridization (SureSelect), bisulfite treated and sequenced. I report in this thesis the 
successful use of this system, which captures 87Mb of the human genome, mainly 
gene promoters, CpG islands and their flanking regions (shelves).  
The main challenge in BS-seq is the bioinformatics analysis, due to the reduced 
complexity of the bisulfite converted reads, and the resulting difficulties in correctly 
mapping the reads on the in silico bisulfite-converted reference genome. 
Next-generation sequencing 
Thanks to next generation sequencing technologies we can now investigate the 
relationships that exist between gene expression and epigenetic players, such as 
histone modifications and DNA methylation, during cell life and tissue differentiation. 
Sequencing technology, efficiency and cost have been improving since 1977, when 
Maxam and Gilbert, and Sanger first described DNA sequencing (Maxam AM and 
Gilbert W, 1977; Sanger F et al., 1977). Advances in automatic capillary sequencing 
technology permitted in 1990 to launch the “human genome project” aimed to 
sequence the entire human genome and whose completeness was announced in 
2001(Lander ES et al., 2001; The International Human Genome Sequencing 
Consortium, 2004; Venter JC et al., 2001). 
NGS was the answer to the ever-growing demand for sequencing better accuracy and 
higher throughput, thus starting a revolution in genomics analysis. Current technologies 
allow the resequencing of the human genome in few days and offer the possibility of 
systematic investigations.  
The most used NGS technologies today available are characterized by physical 
immobilization of the short DNA fragments to be sequenced and their massively parallel 
sequencing (Metzker ML, 2010). 
SOLiD (Applied Biosystems, Life Technologies) 
The SOLiD sequencing technology is based on the immobilization of DNA fragments on 
small beads followed by their amplification by emulsion PCR. To determine the 
sequence of the clonal DNA fragment on each bead, SOLiD uses multiple cycles of 
hybridization, ligation and cleavage. 
The sequencing reaction starts when a universal anchoring primer ligates to a 
sequencing primer that is a fluorescently labelled 8-mer sequence. After the ligation of 
the 8-mer the emitted fluorescence is registered, then the three last nucleotides of the 
8-mer are cleaved and another cycle of ligation starts (Shendure J et al., 2005). The 
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main advantage of the SOLiD technology is that each base is interrogated twice; so 
SOLiD sequencing is very accurate (>99.94%). This re-reading of sequence minimizes 
base-calling errors and makes the SOLiD well suited to high accuracy sampling 
applications such as genome resequencing, polymorphism analysis and BS-seq.  
Solexa/Illumina Genome Analyzer 
In the Solexa/Illumina system, clonal DNA clusters are generated by bridge amplification 
onto the glass surface of the instrument flow cell. It results in a dense array of non-
overlapping fragment sequencing colonies. Each fragment colony is then sequenced 
one base at a time by reversible termination with the cyclical addition of fluorescently 
labelled nucleotides (Bentley DR et al., 2008). 
Ion Proton 
Ion Torrent sequencing technology is based on the release of an hydrogen ion 
whenever a nucleotide is added to a growing DNA strand. DNA fragments are 
immobilized in tiny wells with a semiconductor chip; the four nucleotides floods one by 
one over the wells and the semiconductor registers a pH variation when a nucleotide is 
incorporated in the sequence. The major disadvantage of this technology is the 
susceptibility to the homopolymeric stretch problem, as it was for 454 technology. The 
main advantages are low running cost and sequencing speed. 
Building skeletal muscle: adult myogenesis 
Myogenesis is the process of building functional muscle from precursor cells: in adult 
individuals it occurs when satellite cells, a population of myogenic precursors, provide 
regeneration and muscle growth (Bentzinger CF et al., 2012). 
Transcriptional regulation of myogenesis 
Pax3 and Pax7 transcription factors have a predominant role in the embryonic 
myogenesis, whereas in postnatal life satellite cells respond to environmental stimuli 
supplied by adhesion molecules, growth factors or cytokines. Extracellular stimuli 
activate muscle-specific gene transcription through signalling cascades, mainly p38 
MAPK pathway.  
Quiescent satellite cells express Pax7 and, upon activation and asymmetric division, 
start expressing Myf5. When MyoD expression is upregulated in Pax7+ Myf5+ 
committed satellite cells, they enter a proliferative state and become myoblasts (Mb). 
The differentiation can proceed through myocyte till myotube when MyoD associates to 
E-proteins forming a heterodimer that activates muscle-specific genes. The proliferative 
state of Mb population is maintained thanks to high level of a protein called Inhibitor of 
differentiation (Id), which associates to MyoD and to E-proteins, thus giving origin to 
inactive Id/MyoD and Id/E-protein heterodimers. When the terminal differentiation signal 
reaches the proliferating Mb, MyoD can associate with E-proteins and activate the other 
Muscle regulatory factors (MRFs): early during differentiation Mb express MyoG and, 
later, MRF4 (Berkes CS and Tapscott SJ, 2005). p38 MAPK pathway is essential in the 
onset of this terminal differentiation by mediating (1) phosphorylation of E47, thus 
inducing the MyoD/E47 heterodimer formation, (2) phosphorylation of Muscle enhancer 
factor 2 (MEF2D) and inducing its transcriptional activity (McKinsey TA et al., 2002). 
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In late differentiation, when myotubes are forming, JNK pathway is inhibited; cells exit 
cell cycle and express skeletal muscle structural genes (Brand-Saberi B and Bodo C, 
1999). 
Epigenetic regulation of muscle differentiation 
Mechanisms other than the classic transcription factors control the myogenesis gene 
expression program: epigenetic regulation plays a crucial role in the maintenance of 
quiescence and proliferation states in muscle satellite cells, preventing their 
differentiation. 
DNA methylation appears to be a major repressive mechanism of muscle satellite cell 
differentiation. The demethylation of MyoD promoter and distal enhancer, and of MyoG 
appear to be necessary for starting the differentiation program, but the precise timing 
and mechanism that regulate DNA methylation in adult myogenesis are still unclear. In 
particular, it is debated if methylation/demethylation events cause or follow gene-
expression changes (Barreiro E and Sznaider JI, 2013) 
The in vitro differentiation of Mb to Mt is an excellent model for adult myogenesis. 
Tsumagari K et al. (Tsumagari K et al., 2013) studied DNA methylation of Mb, Mt and 
adult skeletal muscle in order to search for changes in DNA methylation correlated to 
myogenesis. They found that differences between Mb and Mt DNA methylation are less 
than between Mb or Mt and skeletal muscle. In particular, they hypothesize that DNA 
demethylation during muscle differentiation is more likely a consequence of gene 
expression than the cause. 
In quiescent satellite cells and in proliferating myoblasts, PcG proteins maintain muscle 
differentiation specific genes in heterochromatic state with hypoacetylated H3K27me3 
and H3K9me2 histone modifications. H3K27 trimethylation is catalysed by Ying Yang 
protein 1 (YY1), which recruits the Polycomb Repressive Complex to inactive muscle 
gene promoters. Moreover, MyoD and MEF2 interact with histone deacetylases 
(HDACs) in proliferating Mb. 
When myoblasts enter terminal differentiation program, HDACs are removed from 
muscle specific gene promoters, thus allowing histone acetylases (HATs), p300 and 
PCAF to interact with transcription factors and start gene expression. Moreover, MRF2 
recruits TrGX histone methyltransferase that trimethylate H3K4 histone, H3K9me2 and 
H3K27me3 are removed (Perdiguero E et al., 2009), and muscle specific genes can be 
transcribed. 
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Aim of the thesis 
Epigenetics is essential for gene regulation during cell life and organism development: 
the network of chromatin-associated proteins and DNA methylation is the basis of 
chromatin dynamics and leads to gene activation or repression. The aim of my PhD 
project was to create the bases to study the role of epigenetics in human muscle 
differentiation, using primary human myoblasts and myotubes. 
When I began my PhD, epigenetics was still a relatively new field, however it had 
already shown its potential in unravelling the secrets of gene expression. Nevertheless, 
alongside the undisputed worldwide interest on this topic, there was a general lack of 
established procedures. Therefore my initial task was to set-up suitable methods to 
study epigenetics. In particular I wanted to create robust and reliable protocols for 
ChIP-seq and BS-seq that would allow the investigation of the role of epigenetics in 
myogenesis. 
As a further aim I wanted to validate and apply these new procedures to investigate the 
epigenetics involvement in skeletal muscle differentiation and plasticity. Moreover, a final 
goal of my PhD thesis was the integration of the epigenetics results with the findings 
obtained from other lines of research carried out in the laboratory, concerning mRNA 
and miRNA expression in the same experimental model of myogenic cells. 
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Materials and Methods 
Composition of the buffers 
General solutions 
1X PBS: 137mM NaCl, 2.7mM KCl, 10mM Na
2
HPO
4
*2H
2
O, 2mM KH
2
PO
4
, pH 7.4 
 
1X TAE: 40mM Tris, 20mM acetic acid, 1mM EDTA 
 
0.5X TBE: 45mM Tris-borate, 1mM EDTA 
HBSS: 1.26mM CaCl
2
, 0.49mM MgCl
2
*6H
2
O, 0.41mM MgSO
4
*7H
2
O, 5.33mM KCl, 0.44mM KH
2
PO
4
, 138mM 
NaCl, 0.34mM Na
2
HPO
4
*7H
2
O, 5.56mM D-glucose. 
 
ChIP buffers 
 
XChIP 
XChIP Buffer A: 11% HCOH, 0.1M NaCl, 1mM EDTA, 0.5mM EGTA pH8.0, 20mM HEPES pH 7.9 
 
XChIP Buffer B: 0.25% triton-x100, 10mM EDTA, 0.5mM EGTA pH8.0, 20mM HEPES pH7.9 
 
XChIP Buffer C: 0.15M NaCl, 1mM EDTA, 0.5mM EGTA pH8.0, 20mM HEPES pH7.9 
 
XChIP Sonication Buffer: 0.3% SDS, 1% triton-x100, 150mM NaCl, 1mM EDTA, 0.5mM EGTA pH8.0, 
20mM HEPES pH7.9 
 
XChIP dilution buffer: 1% Triton-X 100, 150 mM NaCl, 1 mM EDTA, 20 mM HEPES pH7.9 
XChIP Wash Buffer A: 0.1% SDS, 0.1% NaDOC, 1% Triton-X 100, 150mM NaCl, 1mM EDTA, 0.5mM 
EGTA pH 8.0, 20mM HEPES pH7.9  
 
XChIP Wash Buffer B: 0.1% SDS, 0.1% NaDOC, 1% Triton‐X 100, 500mM NaCl, 1mM EDTA, 0.5mM 
EGTA pH 8.0, 20mM HEPES pH7.9  
 
XChIP Wash Buffer C: 0.25M LiCl, 0.5% NaDOC, 0.5% NP‐40, 1mM EDTA, 0.5mM EGTA pH 8.0, 20mM 
HEPES pH7.9  
 
XChIP Wash Buffer D: 1mM EDTA, 0.5mM EGTA pH 8.0, 20mM HEPES pH7.9  
 
XChIP Elution Buffer: 1%SDS, 0.1M NaHCO3 
 
nChIP 
2X base buffer: 120mM KCl, 30mM NaCl, 10mM MgCl
2
, 0.2mM EDTA, 30mM Tris/Cl pH7.5 
 
nChIP Buffer 1: 0.3M sucrose, 5mM Na Butyrate, 0.1mM PMSF, 0.5mM DTT, 60mM KCl, 15mM NaCl, 
5mM MgCl
2
, 0.1mM EDTA, 15mM Tris/Cl pH7.5 
 
nChIP Buffer 2: 0.3M sucrose, 5mM Na Butyrate, 0.1mM PMSF, 0.5mM DTT, 60mM KCl, 15mM NaCl, 
5mM MgCl
2
, 0.1mM EDTA, 15mM Tris/Cl pH7.5 + 0.8% V/V NP-40 
 
nChIP Buffer 3: 1.2M sucrose, 5mM Na Butyrate, 0.1mM PMSF, 0.5mM DTT, 60mM KCl, 15mM NaCl, 
5mM MgCl
2
, 0.1mM EDTA, 15mM Tris/Cl pH7.5 
 
MNase digestion buffer: 0.3M sucrose, 5mM Na Butyrate, 0.2mM PMSF, 4mM MgCl
2
, 1mM CaCl
2
, 50mM 
Tris/Cl pH7.5 
nChIP Incubation buffer: 150mM NaCl, 20mM Na Butyrate, 5mM EDTA, 0.2mM PMSF, 20mM Tris/Cl 
pH7.4 
 
nChIP Washing buffer 1: 5mM Na Butyrate, 10mM EDTA, 75mM NaCl, 50mM Tris/Cl pH7.5 
 
nChIP Washing buffer 2: 5mM Na Butyrate, 10mM EDTA, 125mM NaCl, 50mM Tris/Cl pH7.5 
 
nChIP Washing buffer 3: 5mM Na Butyrate, 10mM EDTA, 175mM NaCl, 50mM Tris/Cl pH7.5 
 
nChIP Elution buffer: 1% SDS, 50mM NaCl, 5mM EDTA, 20mM Na Butyrate, 0.1mM PMSF, 20mM Tris/Cl 
pH7.5 
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Antibodies used 
Antibody Source Company 
Anti-TBP (cat. no sc-273 X) Rabbit Santa Cruz Biotechnology, Dallas, TX 
Anti-H3K9me3 (cat. no C15410069) Rabbit Diagenode, Liege, Belgium 
Anti-H3K9me3 (cat. no C15410003) Rabbit Diagenode 
Anti-H3K27me3 (cat. no sc.130356 X) Mouse Diagenode 
Normal mouse IgG (cat. no I5381) Mouse Sigma-Aldrich, Saint Louis, MO 
Normal rabbit IgG (included in True MicroChIP kit) Rabbit Diagenode 
 
Cells 
Mouse splenocytes 
One of the aims of this project was to set-up a protocol for chromatin 
immunoprecipitation experiments. Initially in order to perform and assess different ChIP 
protocols splenocytes were used due to the ease of obtaining high number of cells. The 
number of splenocytes obtained from a single mouse spleen is ~100million. 
Mouse dissection and spleen isolation 
Fresh splenocytes were isolated from the spleen of a healthy mouse (kindly provided by 
Dr. P. Braghetta, Dept. Biomedical Science, Univ. Padua). 
1. Put the mouse on the bench with the abdomen facing up. 
2. Grab hold the skin at the urethral opening using a forceps, and cut the skin 
along the ventral midline till the groin. 
3. Remove the peritoneal muscle wall without touching the internal organs. 
4. The spleen is a dark-red organ in the left side of the abdomen, close to the 
pancreas and behind the intestine. After finding the spleen, cut its connections 
with internal organs and remove it. 
5. Prepare a single-cell suspension of splenocytes in 3ml of PBS and count the 
cells in using a Neubauer counting chamber. 
6. Divide the cell suspension in several aliquots containing 20million cells each and 
centrifuge for 8 min at 200rcf, RT. 
7. Aspirate all the supernatant, snap-freeze the aliquots in liquid nitrogen and store 
at -80°C for up to 1 year. 
C2C12 cell culture 
The immortalised C2C12 cell line is a subclone (Blau HM et al., 1985) of the mouse 
myoblast cells, C2. These cells are a model for studying skeletal muscle differentiation 
due to their capacity of in vitro myogenic differentiation. 
The cells grow in adhesion on a plastic surface and are maintained at 37°C in a 
humidified incubator with 6% CO2. Undifferentiated proliferating Mb grow in DMEM 
(GIBCO, Life Technologies, Carlsbad, CA) with 10% FBS (GIBCO) and 50µg/ml 
Gentamycin (GIBCO) (referred to as “growth medium”). Differentiation of Mb to 
myotubes (Mt) is triggered by low serum conditions. Differentiation medium: DMEM with 
2% horse serum (GIBCO) and 50µg/ml Gentamycin. 
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Cell culture and passage 
Proliferating Mb are maintained in 175cm2 flasks (SARSTEDT, Nümbrecht, Germany) 
with 25ml of growth medium. When growing in these conditions cells reach confluence 
at ~3*106 cells. 
When the Mb in a flask reach 50% of confluence (no contact or very few contacts 
between cells) they were used for ChIP experiments as Mb, or the cells were seeded 
into new flasks following the procedure reported here. 
1. Remove and discard growth medium and rinse twice with 10ml of Dulbecco's 
PBS (calcium and magnesium free) at RT. 
2. Detach cells by trypsinization: add 2.5ml of 1X Trypsin-EDTA solution (GIBCO) 
in each flask and wait until cells detach, usually 2-3’. 
3. Add 5ml of FBS to the flask and collect cells in a 15ml tube. 
4. Centrifuge the cells at 150rcf for 8’, discard supernatant and suspend cells in 
10ml of growth medium. 
5. Count the cells using a Neubauer chamber and plate 3x105 cells in new flasks 
with 25ml of growth medium. 
Instead of dividing the cells to maintain the cell culture, the cells can be collected and 
frozen for future use. Mb dry pellets can be snap-frozen in liquid nitrogen and stored at 
-80°C for up to 1 year for future applications. 
C2C12 myogenic differentiation 
When C2C12 cells in a flask are 70-80% confluent, the substitution of the growth 
medium with the low-serum differentiation medium induces differentiation. 
1. Remove and discard the growth medium and rinse the cells once with 
Dulbecco's PBS (without calcium and magnesium) at RT. 
2. Add 25ml of differentiation medium and differentiate for 9 days, replacing 
medium every 3 days. Myotubes at this stage can be used immediately for ChIP 
experiments or can be detached and stored at -80°C for future experiments. 
3. Detach cells by trypsinization: add 2.5ml of 1X Trypsin-EDTA solution to each 
flask and wait until cells detach. 
4. Add 5ml of FBS to the flask and collect cells in a 15ml tube. 
5. Centrifuge the cells at 150rcf for 8’, snap-freeze the dry pellet in liquid nitrogen 
and store at -80°C for up to 1 year for future applications. 
CHQ5B primary cell culture 
CHQ5B is a primary cell line of human Mb initially provided by Dr. V. Mouly (URA, 
CNRS, Paris, France). Accordingly to French legislation and ethical rules CHQ5B 
human Mb were isolated from the quadriceps of a 5-day infant female without any sign 
of neuromuscular disorders. CHQ5B cells reach proliferative senescence after 
approximately 50 divisions. Mb can differentiate in vitro by changing the medium 
composition (Figure 1); the cells grow in adhesion on plastic surfaces and are 
maintained at 37°C in a humidified incubator with 6% CO2. 
Undifferentiated proliferating Mb grow in a medium composed of DMEM with 20% FBS 
and 50µg/ml Gentamycin, and to induce differentiation growth medium is switched with 
differentiation medium: DMEM with 2% horse serum and 50µg/ml Gentamycin. 
 18 
Both cell culture and cell differentiation conditions are analogous to that described for 
C2C12 cells, except for growth medium composition. 
 
Cell counting with Neubauer chamber or Hemocytometer 
Cell counting is required to monitor cell growth and ensure experimental reproducibility 
in the applications that require a precise initial number of cells, such as ChIP 
experiments. 
The hemocytometer is a thick glass slide containing 2 counting chambers with laser-
etched grids of perpendicular lines. Volumes of both entire grid and single quadrants 
are known and this allows the estimation of cell concentration in the initial cell 
suspension. 
The number of cells in the chamber is determined by direct counting under an inverted 
microscope and this number is used to calculate the concentration of the initial cell 
suspension. After counting the cells in the 4 corners, calculate the average number of 
cell per quadrant by dividing the sum four times; multiply by 10,000 and then multiply 
by the dilution used to obtain, cell/ml. 
DNA extraction 
If starting with whole cells: 
1. Resuspend 3million cells (as dry-pellet, both fresh or -80°C stored) in 1ml PBS 
with 2% SDS (Sigma-Aldrich) and 1mM EDTA (Sigma-Aldrich). If starting with 
more cells, scale accordingly the volume of PBS-SDS-EDTA buffer. 
2. Aliquot 200µl of the cell suspension in 1.5ml microcentrifuge tubes. 
Phenol-chloroform nucleic acid extraction 
1. Add 1 volume of TE saturated phenol pH10.5 (Sigma-Aldrich) mix vigorously by 
vortexing, and incubate at RT till the formation of two phases; 
2. Centrifuge 5’ 16,100rcf at RT, then transfer the upper aqueous phase in a new 
1.5ml microcentrifuge tube. 
3. Add 1 volume of chloroform (Carlo Erba Reagents, Arese-Milano, Italy) to the 
aqueous phase and mix by inversion. 
Figure 1| CHQ5B is a human primary cell culture of myoblasts (on the left panel) that can differentiate in 
vitro into myotubes (right panel), by serum limitation in the culture medium. 
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4. Centrifuge 5’, 16,100rcf at RT and transfer the upper aqueous phase in a new 
1.5ml microcentrifuge tube; 
5. Add 1 volume of chloroform and repeat the centrifugation step. 
6. Transfer the upper phase into a new 1.5ml microcentrifuge tube and proceed 
with isopropanol/salt or ethanol/salt nucleic acid precipitation. 
Isopropanol/salt or ethanol/salt nucleic acid precipitation 
1. Add 5M NaCl (Sigma-Aldrich) to a final concentration of 250mM and 1 volume 
of isopropanol (Carlo Erba Reagents) or, alternatively, 2 volumes of absolute 
ethanol (Carlo Erba Reagents). The use of isopropanol or ethanol will be 
specified case by case, but if not specified, 1 volume of isopropanol is used. 
2. Incubate 4-16h at -20°C, then centrifuge 30’ 16,100rcf 4°C and discard the 
supernatant. 
3. Wash the pellet with 500µl of freshly prepared 70% EtOH. 
4. Centrifuge 20’ 16,100rcf 4°C and discard supernatant. 
5. Repeat the washing and centrifugation steps. 
6. Aspirate all the supernatant with a micropipette tip and leave the pellet to air-
dry. 
7. Resuspend the pellet in a suitable volume of Low TE buffer or ultrapure water 
(Sigma-Aldrich). Volume and buffer for resuspending the DNA pellet will be 
specified case by case. 
Lithium Chloride RNA precipitation 
When extracting DNA from cells RNA contamination is always present and high 
concentration of lithium chloride allows the selective precipitation of RNA, while DNA 
remains in solution. 
1. Add 1/3 of the initial volume of 8M LiCl (Sigma-Aldrich) in the nucleic-acid 
containing solution and incubate on ice for 4h. 
2. Centrifuge 40’ 16,100rcf 4°C. 
3. Transfer the DNA-containing supernatant in a new microcentrifuge tube and 
discard the RNA-containing pellet. 
4. Repeat the isopropanol/salt or ethanol/salt DNA precipitation to concentrate the 
DNA. 
The quantification of the extracted DNA is performed both with NanoDrop™1000, 
Thermo Fisher Scientific, Waltham, MA) and Qubit® 2.0 fluorometer (Invitrogen, Life 
Technologies, Carlsbad, CA). Quality evaluation is performed on a 0.6% w/v agarose 
gel electrophoresis in 1X TAE buffer. 
 
 
DNA and chromatin fragmentation 
For both ChIP-seq and BS-seq applications the COVARIS™ S2 Ultrasonicator (Covaris 
Inc., Woburn, MA) was used to efficiently fragment chromatin and DNA.  
Below are reported the chromatin and DNA fragmentation protocols used for this 
project. 
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Mouse splenocytes chromatin shearing 
Sample volume: 2ml 
Sample Buffer: XChIP sonication Buffer 
Water level: 12 
Water bath temperature: 4-8°C 
Tubes: 16×65mm TC13 glass tubes 
Mode: frequency sweeping 
Duty cycle: 20% 
Intensity: 10 
Cycles per burst: 1000 
Time: 60s 
Number of cycles: 10 
C2C12 chromatin shearing 
Sample volume: 1ml 
Sample Buffer: XChIP sonication Buffer 
Water level: 12 
Water bath temperature: 4-8°C 
Tubes: 16×65mm TC13 glass tubes 
Mode: frequency sweeping 
Duty cycle: 20% 
Intensity: 10 
Cycles per burst: 1000 
Time: 60s 
Number of cycles: 8 
CHQ5B nuclei chromatin shearing 
Sample volume: 1ml 
Sample Buffer: XChIP sonication Buffer 
Water level: 12 
Water bath temperature: 4-8°C 
Tubes: 16×65mm TC13 glass tubes 
Mode: frequency sweeping 
Duty cycle: 20% 
Intensity: max 
Cycles per burst: 1000 
Time: 60s 
Number of cycles: 8 
CHQ5B chromatin shearing for True MicroChIP kit 
Sample volume: 100µl 
Sample buffer: 25% Lysis Buffer tL1 + 
75% HBSS 
Water level: 15 
Water bath temperature: 3-5°C 
Tubes: AFA™ fiber microtube 
Mode: frequency sweeping 
Duty cycle: 5% 
Intensity: 2 
Cycles per burst: 200 
Time: 60s 
Number of cycles: 10 
DNA fragmentation for SureSelect Methyl-Seq Target Enrichment 
Sample volume: 130µl 
Sample buffer: 1X Low TE 
Water level: 15 
Water bath temperature: 4-7°C 
Tubes: AFA™ fiber microtubes 
Mode: frequency sweeping 
Duty cycle: 20% 
Intensity: 10 
Cycles per burst: 1000 
Time: 60s 
Number of cycles: 10 
DNA fragmentation after bisulfite treatment (MeSS v2) 
Sample volume: 130µl 
Sample buffer: 1X Low TE 
Water level: 15 
Water bath temperature: 4-6°C 
Tubes: AFA™ fiber microtubes 
Mode: frequency sweeping 
Duty cycle: 10% 
Cycles per burst: 200 
Intensity: 4 
Time: 60” 
Number of cycles: 2 
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DNA fragmentation before bisulfite treatment (MeSS v1 and Ion Proton BS-seq) 
Sample volume: 130µl 
Sample buffer: 1X Low TE 
Water level: 12 
Water bath temperature: 6-8°C 
Tubes: AFA™ fiber microtubes 
Mode: frequency sweeping 
Duty cycle: 10% 
Cycles per burst: 200 
Intensity: 5 
Time: 60” 
Number of cycles: 3 
XChIP-DNA fragmentation for SOLiD fragment library preparation 
Sample volume: 130µl 
Sample Buffer: 1X Low TE Buffer 
Water level: 15 
Water bath temperature: 4-6°C 
Tubes: AFA™ fiber microtube 
Mode: frequency sweeping 
Duty cycle: 20% 
Intensity: 5 
Cycles per burst: 200 
Time: 60s 
Number of cycles: 6 
nChIP-DNA fragmentation for Ion Proton fragment library preparation 
Sample volume: 50µl 
Sample Buffer: 1X Low TE Buffer 
Water level: 12 
Water bath temperature: 6-8°C 
Tubes: AFA™ fiber microtube 
Mode: frequency sweeping 
Duty cycle: 10% 
Intensity: 2 
Cycles per burst: 200 
Time: 40s 
Number of cycles: 1 
 
Agencourt® AMPure® XP beads DNA purification 
Fragmented DNA purification was used either to change buffer composition or to purify 
libraries from adapters. 
1. Add a suitable volume of Agencourt® AMPure® XP (Beckman Coulter, Brea, CA) 
beads were added to the sample. The ratio between the volume of beads used 
and the initial volume of the sample will be specified every time. 
2. Pipet to mix, pulse-spin and incubate at RT for 5’. 
3. Pulse-spin and place the tube in a magnetic rack for 3’, then remove and 
discard the supernatant without disturbing the beads. Do not remove the tube 
from the magnet. 
4. Without removing the tube from the magnet, wash the beads with 500µl of 
freshly prepared 70% EtOH. Incubate for 30”, turning the tube in the magnet to 
move the beads. When the solution is clear, remove and discard the SN without 
disturbing the pellet. 
5. Repeat the washing step. 
6. To remove residual ethanol: pulse-spin the tube, place it back on the magnet 
and carefully remove the remaining supernatant. 
7. Without removing the tube from the magnetic rack, leave the beads to air-dry at 
RT for ≤5’. 
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8. Remove the tube from the magnetic rack and add a suitable volume of H2O 
or LowTE buffer directly on the pellet to dissolve the beads. The volume and 
buffer for resuspending the DNA pellet will be specified case by case. 
9. Pipet 5 times to mix, vortex for 10” 
10. Pulse-spin and place the tube back on the magnetic rack for 2’. 
11. Transfer the supernatant in a new 1.5ml LoBind (Eppendorf, Hamburg, 
Germany) tube without disturbing the pellet. 
Nucleic acid quantification and quality evaluation 
Quality and concentration of DNA were determined using both NanoDrop™ 
spectrophotometer and agarose gel electrophoresis. The concentration was then 
more accurately determined using the Qubit® 2.0 fluorometer. 
NanoDrop™ spectrophotometer 
NanoDrop™ spectrophotometer (NanoDrop™1000, Thermo Fisher Scientific) can 
measure the absorbance of the nucleic acid solution at 260nm (A260). 
An A260 of 1 is equivalent to a concentration of approximately 50µg/ml for double 
stranded DNA and of 33µg/ml for single stranded DNA. The settings for single 
stranded DNA are used for the quantification of bisulfite-treated DNA. 
The presence of contaminants in the solution can be estimated by observing the 
A260/280 and the A260/230 ratios. As a general statement we consider a sample 
clean if these values are above 1.80; lower values indicates the presence of 
contaminants. All RNA, salts, proteins and solvents alter the quantification of the 
DNA. 
Qubit® 2.0 fluorometer 
The Qubit® 2.0 fluorometer (Life Technologies, Carlsbad, CA) permits an accurate, 
specific and high sensitive quantification of even low concentration of DNA. It uses 
a fluorimetric technology in which fluorescent probes emit a signal only when bound 
to their specific target molecule. The presence of proteins, RNA, salts or detergent 
contaminants in the solution does not interfere with the accuracy of the DNA 
quantification. 
The dsDNA high sensitivity kit used during this project is highly selective for double-
stranded DNA and is accurate for initial sample concentrations between 10pg⁄µl 
and 100ng⁄µl. Highly concentrated samples must be properly diluted. 
Samples were prepared for the assay following instructions: 
1. Prepare the working solution by diluting the DNA HS fluorescent dye 1:200 
in DNA HS buffer. 200µL of working solution are required for each sample. 
2. Set-up one thin-well, clear, 0.5ml assay tube (Qubit® assay tube) for each 
sample and mix reagents following the table here reported: 
Working solution  180-199µl 
DNA sample   1-20µl 
______________________________________ 
Total    200µl 
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3. Vortex the tubes for 2-3”, then pulse-spin. 
4. Incubate in the dark for 2’ at RT, then take the read on the Qubit® 
fluorometer with dsDNA HS settings. 
5. Calculate the concentration of the initial sample using the dilution calculator 
feature of the Qubit® 2.0 fluorometer. 
6. Fluorometric assay yielded a quantification of the DNA in the samples and 
could be compared with the data obtained using NanoDrop™. 
Agarose gel electrophoresis 
Agarose gel electrophoresis permits the separation of DNA fragments depending on 
their length and can be used to estimate quantity, quality and dimensions of DNA. 
Depending on buffer composition and agarose concentration different information 
can be obtained. The electrophoretic run is performed at 100V for 40’ in a 10cm 
long gel. The signal can be seen on a transilluminator (a UV light box), due to the 
fluorescent dye added to the agarose. Ethidium bromide can be added to the 
agarose before pouring at a final concentration of 0.5ug/ml. However, as an 
alternative SYBR® Green can be used. 
DNA integrity check 
To evaluate the integrity and purity of a DNA extraction the agarose gel 
electrophoresis is performed in 1X TAE buffer. The agarose gel is 0.6% w/v agarose 
(Sigma-Aldrich) in 1X TAE with 0.5µg/ml of Ethidium Bromide (Sigma-Aldrich). 
This method permits to determine the integrity of the DNA and allows its indirect 
quantification by comparing the intensity of the DNA signal with the intensity of the 
ladder, whose concentration is known. Agarose gel electrophoresis permits to see 
the presence of RNA, proteins, salts or detergent contaminations. 
Estimation of DNA dimensions 
After sonication steps of at the end of a library preparation, a preliminary idea on the 
dimensions of the DNA is given by gel electrophoresis. Depending on the expected 
fragment dimensions the electrophoresis can be performed in TAE or in TBE buffer, 
with the last giving the best resolution for low molecular weight DNA. 
To estimate DNA dimensions I used the 1.8% w/v agarose gel in 1X TAE or 0.5X 
TBE buffer with 0.5µg/ml Ethidium Bromide. The buffer choice is specified every 
time an electrophoresis is cited in the protocol. 
For precise evaluation and visualization of DNA dimensions the tool of choice is the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). 
Agilent 2100 Bioanalyzer 
Agilent 2100 Bioanalyzer is a microfluidic-based platforms used for sizing, 
quantification and quality evaluation of nucleic acid preparation. 
Readings of DNA after sonication steps or after library preparation were done using 
the Agilent 2100 Bioanalyzer by BMR genomics using DNA HS kit and chip. 
Agilent Bioanalyzer DNA HS kit can accurately analyze samples with a DNA 
concentration between 10 and 800pg/µl. For this thesis, samples were quantified 
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using the Qubit® 2.0 fluorometer, diluted in Low TE buffer till the concentration of 
500pg/µl and then submitted for Agilent analysis. 
 
XChIP-seq homemade protocol 
The set-up of the chromatin preparation protocol was conducted on the basis of a 
protocol for ChIP-seq kindly provided by Dr. Mokry (Mokry M et al., 2010). 
Set-up of chromatin preparation on mouse splenocytes 
The initial setup of the crosslinking and shearing conditions for ChIP experiments 
was conducted on mice splenocytes. 
1. Defrost one ice one 20million cell-aliquot of mice splenocytes. 
2. Resuspend the pellet in 1ml of RT PBS and transfer the cell suspension in a 
15ml falcon tube containing 9ml of RT PBS. 
3. Add 1ml (1/10 Vi) of a XChIP Buffer A and incubate RT for 20’ with 
occasional mixing by inversion. 
4. Add glycine to a final concentration of 0.125M in order to block cross-linking 
and incubate RT for 5’. 
5. Centrifuge 5’ 1,200rcf 4°C and discard the supernatant. 
6. Resuspend pellet in 10ml of ice-cold XChIP Buffer B + PIC and incubate on 
ice for 10’. This step allows the nuclei isolation. 
7. Centrifuge 5’ 1200 rcf 4°C and discard the supernatant. 
8. Resuspend the pellet in 10ml of ice-cold XChIP Buffer C + PIC and incubate 
on ice for 10’. 
9. Centrifuge 10’ 2500rcf 4°C and aspirate the supernatant. 
10. Resuspend the pellet in 2ml (1ml every 10million cells) of ice-cold XChIP 
Sonication Buffer + PIC. 
11. Incubate on ice for 5’ and then sonicate using the COVARIS with the 
program specified below in the Covaris section. 
12. Centrifuge 20’ 4°C 13200rcf, and transfer the SN in a new microcentrifuge 
tube (use 75µl to check the fragmentation). 
13. Sheared chromatin can be used immediately or can be snap-frozen in liquid 
nitrogen and stored at ‐80°C for up to 6 months. 
  
Set-up of chromatin preparation on C2C12 
If starting from fresh not frozen C2C2 cells, either Mb or Mt, remove and discard the 
culture medium and add 10ml of DMEM + 10% FBS directly onto the cell layer. 
If starting with a frozen pellet, defrost cell pellet on ice, add 1ml of DMEM + 10% 
FBS and transfer the cell suspension in a 15ml falcon tube containing 9ml of DMEM 
+ 10% FBS. 
Each chromatin preparation is performed on 10million cells. 
1. Add 270µl of 37% formaldehyde (Sigma-Aldrich), immediately swirl gently 
and incubate RT for 12’ for cross-linking. 
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2. Add Glycine (Sigma-Aldrich) to a final concentration of 0.125M to stop 
cross-linking, swirl gently to mix and incubate RT for 5’. 
3. Remove the PBS/Formaldehyde/glycine solution and from this point onward 
work on ice. 
4. Rince the flask twice with 10ml of ice-cold PBS. 
5. Detach the cells by scraping in 5ml of ice-cold PBS and transfer the fixed-
cell suspension in a 15ml falcon tube. 
6. Rinse the flask with other 5ml of ice-cold PBS + 1X Protease Inhibitor 
Cocktail (Roche, Basel, Switzerland) and transfer the remaining cells in the 
15ml falcon tube. 
7. Centrifuge 400rcf 4°C 8’. 
8. Remove and aspirate as much supernatant as you can, paying attention not 
to disturb the cell pellet. 
At this point you can proceed immediately with cell lysis and chromatin 
shearing or you can snap-freeze the cross-linked cells in liquid nitrogen and 
store them at -80°C for up to 6 months. 
9. Resuspend pellet in 10ml of ice-cold XChIP Buffer B + PIC and incubate on 
ice for 10’. 
10. Centrifuge 5’ 1200 rcf 4°C and discard the supernatant. 
11. Aspirate the supernatant. 
12. Resuspend the pellet in 10ml of ice-cold XChIP Buffer C + PIC and incubate 
on ice for 10’. 
13. Centrifuge 10’ 2500rcf 4°C and aspirate the supernatant. 
14. Resuspend the pellet in 1ml of ice-cold XChIP Sonication Buffer + PIC, 
incubate on ice for 5’ and then sonicate using the COVARIS as specified in 
the dedicated section. 
15. Centrifuge 20’ 4°C 13200rcf, and transfer the SN in a new microcentrifuge 
tube (use 75µl to check the fragmentation). 
16. Sheared chromatin can be used immediately or can be snap-frozen in liquid 
nitrogen and stored at ‐80°C for up to 6 months. 
 
Home-made protocol for ChIP-seq on CHQ5B 
Cross-linking and harvest CHQ5B for ChIP-experiments 
For ChIP experiments CHQ5B Mb cells are collected at ~50% of confluency, and 
Mt after 9 days of differentiation. Each chromatin preparation is performed using 
~10 million of fresh cells. 
1. Discard the medium and wash each bottle twice with RT PBS. 
2. Scrape cells in 10 ml of RT PBS and collect cell suspension in 50ml Falcon 
tubes. 
3. Centrifuge 10’ 150rcf 4°C and discard the SN. 
4. Resuspend cell pellet in 5ml of XChIP buffer B + PIC (Roche) and incubate 
10’ on ice with occasional mixing by !inversion. 
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5. Centrifuge 30’ at 2,500rcf 4°C, and carefully discard the SN. 
6. Resuspend pellet in 10 ml of PBS + PIC, add 1ml of XChIP buffer A + PIC, 
and incubate 10’ on ice and 5’ RT with occasional mixing by inversion. 
7. Centrifuge 30’ 2500rcf 4°C, and discard SN. 
8. Resuspend pellet in 10ml XChIP buffer C + PIC, incubate 10’ on ice !with 
occasional mix by inversion. 
9. Centrifuge 10’ 2000rcf 4°C, discard SN. 
10. Resuspend pellet in 1ml of XChIP sonication buffer + PIC (use 75µl to check 
chromatin integrity). 
11. Sonicate with Covaris S2 for 8’ with the settings specified in the Covaris 
section. 
12. Centrifuge 20’ 4°C 13200rcf, and transfer the SN in a new microcentrifuge 
tube (use 75µl to check the fragmentation). 
Sheared chromatin can be used immediately or can be snap-frozen in liquid 
nitrogen and stored at ‐80°C for up to 6 months. 
Chromatin integrity check 
1. Add an equal volume (75µl) of XChIP dilution buffer to the 75µl chromatin 
samples. 
2. Add 5M NaCl to a final concentration of 200mM and incubate 5h at 65°C 
with occasional mixing to reverse crosslinking. 
3. Extract once with phenol and twice with chloroform. Briefly: 
4. add 1 volume (150µl) of TE-saturated phenol pH10.5 to the sample and mix 
10” by vortexing; 
5. centrifuge 13,800rcf for 5’ and the transfer the upper aqueous phase in a 
new microcentrifuge 1.5ml tube; 
6. add 1 volume (150µl) of chloroform and mix by inversion; 
7. centrifuge 13,800rcf for 5’ and the transfer the upper aqueous phase in a 
new microcentrifuge 1.5ml tube; 
8. repeat once the previuos two steps. 
9. Proceed with an Ethanol/salts DNA precipitation. 
10. Quantify DNA at NanoDrop and load 500 ng of DNA in a 1% 
w/v !agarose/TAE gel. 
11. Check the pre-sheared chromatin integrity and the correct fragmentation. 
Protein A/G preparation 
Each Immunoprecipitation experiment required 5 million cells. 
1. For 5million cells mix 75µL proteinA and 75µL proteinG 
sepharose(Pharmacia, Upsala, Sweden) in a 2ml LoBind Eppendorf tube. 
2. Centrifuge 1,200rcf 4°C 5’ and carefully remove SN. 
3. Wash the pellet with 1.4ml of XChIP incubation buffer + 0.1% BSA. 
4. Centrifuge 1,200rcf 4°C 5’ and carefully remove SN. 
5. Repeat the last two washing steps twice. 
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6. Add 1.5ml of ChIP incubation buffer + 0.1% BSA to the beads and incubate 
12-16h at 4°C on a rotating wheel. 
Immunoprecipitation 
1. Dilute the chromatin 1:1 with XChIP dilution buffer. 
2. Add 3µg of the antibody of interest (TBP and H3K9me3) and incubate for 3h 
at 4°C on a rotating wheel. 
3. At the end of the 3h-incubation, centrifuge the Protein A/G sepharose 
mixture for 5’ 1,200rcf 4°C, remove the supernatant and add the ChIP 
sample (chromatin + antibody of interest) to the beads-containing tube. 
4. Incubate 12-16h at 4°C on a rotating wheel. 
Washing and elution 
1. At the end of the 16h incubation, centrifuge the samples 5’ 1,200rcf 4°C 
and remove the supernatant. 
2. Wash the pellet twice with 1.7ml of ice-cold XChIP Wash Buffer A and 
incubate at 4°C on a rotating wheel for 7’. 
3. Centrifuge 5’ 1,200rcf 4°C and remove the supernatant. 
4. Wash the pellet once with 1.7ml of ice-cold XChIP Wash Buffer B and 
incubate at 4°C on a rotating wheel for 7’. 
5. Centrifuge 5’ 1,200rcf 4°C and remove the supernatant. 
6. Wash the pellet once with 1.7ml of ice-cold XChIP Wash Buffer C and 
incubate at 4°C on a rotating wheel for 7’. 
7. Centrifuge 5’ 1,200rcf 4°C and remove the supernatant. 
8. Wash the pellet twice with 1.7ml of ice-cold XChIP Wash Buffer D and 
incubate at 4°C on a rotating wheel for 7’. 
9. Centrifuge 5’ 1,200 rcf 4°C and remove the supernatant. 
10. Remove all the supernatant and resuspend the pellet in 1.2ml of RT XChIP 
Elution Buffer and incubate for 30’ on a rotating wheel at RT. 
11. Centrifuge 2,000rcf 10’ RT and collect the supernatant in 3 new 1.5ml 
LoBind Eppendorf tubes (400µl each). Discard the pellet. 
12. Add 5M NaCl to a final concentration of 250mM and incubate at 65°C for 
5h with occasional mixing to reverse crosslinking. 
Phenol/chloroform DNA extraction and Ethanol/salt concentration 
1. After the 5h-incubation add 1 volume of TE saturated phenol pH10.5, mix 
by vortexing and centrifuge 16,100rcf 5’ RT. 
2. Transfer the upper aqueous phase in a new 1.5ml LoBind Eppendorf tube 
and add 1 volume of chloroform. 
3. Mix by inversion and centrifuge 15,600rcf 5’ RT. 
4. Repeat the previous two steps. 
5. Transfer the upper aqueous phase in a new 1.5ml LoBind Eppendorf tube. 
6. Add 5µg of Glycogen, 3M NaAc to 300mM final concentration and 1ml of 
ice-cold absolute Ethanol. 
7. Mix by vortexing and incubate 12-16h at -20°C. 
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8. Centrifuge 16,100rcf 30’ 4°C, discard the supernatant and wash the pellet 
with 70% Ethanol. 
9. Repeat the previous step once and centrifuge 16,100rcf 20’ 4°C. 
10. Remove all the supernatant and leave the pellet to air-dry. 
11. Dissolve the pellet in 30µl of SIGMA H2O and collect the resuspended 
pellets of the same sample in one tube (90µl). 
Semi-quantitative PCR 
To evaluate the enrichment of immunoprecipitated samples I performed a 
semiquantitative PCR. 
The primers I used: 
SAT2 FOR 5’–CTGCAATCATCCAATGGTCG–3’ 
SAT2 REV 5’–GATTCCATTCGGGTCCATTC–3’ 
FOS FOR 5’–CATCTGCGTCAGCAGGTTTCCAC–3’ 
FOS REV 5’–TGAGCATTTCCCAGTTCCTGTCT–3’ 
 
1µl of immunoprecipitated DNA was used as template for semiquantitative PCR. 
PCR Reaction Mix (for 1 sample): 
H2O    13.6µl 
5X GoTaq Reaction Buffer 4µl 
Template   1µl 
10mM dNTPs   0.4µl 
10µM FOR Primer  0.4µl 
10µM REV Primer  0.4µl 
GoTaq [5U/µl]   0.2µl 
____________________________ 
Total    20µl 
 
Thermal cycler program: 
 
95°C 4’ 
 
   95°C 20” 
   54°C 30”            x40times 
   72°C 30” 
 
   72°C 7’ 
   4°C hold 
 
Every 2 cycles, starting from 26 till 40, a sample was removed from the thermal 
cycler and the reaction was stopped on ice, to check the amplification. Load the 
sample on a 1% w/v TAE-agarose gel to check amplification. 
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Library preparation 
I prepared SOLiD sequencing libraries from four immunoprecipitated samples: Mb 
TFIID, Mt TFIID, Mb H3K9me3, Mt H3K9me3. 
Buffers and enzymes that are used in this section are all included in the SOLiD 
Fragment Library Preparation Kit. 
Sonication and end-repair of the immunoprecipitated DNA 
1. The immunoprecipitated DNA was fragmented as reported in the section 
“Fragmentation of the IP DNA for SOLiD fragment library preparation”. 
2. Quantitate the DNA using the Qubit® fluorometer and check the fragment 
size with Agilent Bioanalyzer. 
3. End-polish the DNA to obtain 5’-phosphorilated, blunt-ended dsDNA 
fragments. For each immunoprecipitated sample set-up the reaction as 
follows: 
Sheared DNA   130µl 
5X Reaction Buffer  40µl 
10mM dNTPs   8µl 
End Polishing Enzyme E1 4µl 
End Polishing Enzyme E2 16µl 
H2O    2µl 
_____________________________ 
Total    200µl 
4. Vortex to mix and spin. 
5. Incubate RT for 30’. 
6. Purify the DNA with 1.5volumes of Agencourt® AMPure® XP beads and 
elute in 60µl of Low TE buffer. 
 
Adapters ligation 
1. Set-up the adapters ligation mix: 
End-Polished DNA  60µl 
5X Ligation Buffer  20µl 
Ligase    9µl 
50µM P1 adaptor  0.5µl 
50µM P2 barcoded adaptor 0.5µl 
H2O    9µl 
_____________________________ 
Total    100µl 
2. Vortex and spin. 
3. Incubate RT for 15’, then proceed with an Agencourt® AMPure® XP beads 
DNA purification using 1.5 volumes of beads. 
4. Elute the DNA in 12µl of Low TE buffer. 
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Library amplification 
Before emulsion-PCR, bead-enrichment and sequencing, the library is PCR-
amplified in order to obtain an amount of DNA suitable for sequencing procedures. 
1. Library amplification mix: 
 Adapters-ligated DNA   12µl 
 50µM P1 primer   1.8µl 
50µM P2 primer   1.8µl 
Platinum® PCR Amplification Mix 72µl 
H2O     2.4µl 
___________________________________ 
Total     90µl 
2. Vortex and spin. 
3. Incubate in the thermal cycler with the following program: 
72°C 20’ 
95°C 5’ 
 
95°C 15” 
62°C 15”            x10 times 
70°C 1’ 
 
70°C 5’ 
4°C hold 
4. Purify the amplified library using 1.5v of Agencourt® AMPure® XP beads. 
Elute in 20µl of Low TE Buffer. 
5. Quantitate the amplified library with the DNA HS kit on the Qubit® 
fluorometer. 
6. Check the quality of the library with Agilent Bioanalyzer. If adapters are 
visible on the Agilent profile, repeat the AMPure® XP beads purification 
step. 
 
The sequencing core of Prof. Valle Group performed emulsion PCR, bead-
enrichment and SOLiD sequencing. 
 
Diagenode True MicroChIP kit 
For this ChIP-seq experiment I used 100,000 CHQ5B Mb for each 
immunoprecipitation. In particular, I performed ChIP-seq with Anti-H3K4me3, -
H3K9ac and -H3K27me3 antibodies and a control. 
Buffers and enzymes whose company is not specified in this section are included in 
the Diagenode True MicroChIP kit. 
Crosslinking protocol 
Use only fresh cell flasks. 
1. Place PBS, cell culture medium and Trypsin-EDTA at room temperature. 
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2. Since using adherent cells, discard culture medium to get rid of dead cells 
and was the cell layer by adding 10ml PBS. 
3. Detach cells by tripsinization and collect by adding medium (DMEM + 10% 
FBS). 
4. Transfer the cell suspension in a 15ml Falcon tube and centrifuge 150rcf 8’ 
RT. 
5. Discard the supernatant and resuspend the cells in 3ml DMEM+10% culture 
medium and count the cells using Neubauer chamber. Cells must be in 
single-cell suspension. 
The amount of cells to use for fixation is calculated as “number of IP to 
perform + 1 control” x “100,000cells/IP” and a unique batch of chromatin 
was fixed. 
6. Aliquot the number of cells to be fixed as a unique batch in a 1.5ml tube 
and add DMEM + 10% FBS to 1ml final volume. 
7. Add 27µl of 37% Formaldehyde to the 1ml-sample and invert the tube 
immediately two or three times to ensure complete mixing. 
8. Incubate 10’ RT with occasional manual agitation. 
9. Add 115µl of 1.25M Glycine to the sample and immediately mix by inversion 
4-5 times. 
10. Incubate RT for 5’. 
a. From this point onward work on ice! 
11.  Centrifuge 300rcf 10’ 4°C. 
12. Aspirate the supernatant slowly and leave approximately 30µl of the solution 
in order not to remove the crosslinked cells. 
13. Wash the crosslinked cells with 1ml of ice-cold HBSS containing PIC: 
a. add 1ml of HBSS + PIC and gently vortex the tube to completely 
resuspend he cells; 
b. centrifuge 300rcf 10’ 4°C 
14. Aspirate the supernatant and keep cell pellet on ice. Proceed directly to cell 
lysis or, if desired, the cell pellet can be snap-frozen and stored at -80°C for 
up to 2 months. 
Cell lysis and chromatin shearing 
1. Prepare Lysis Buffer: 
a. warm Lysis Buffer to RT (make sure there are no crystals in the Lysis 
Buffer before using); 
b. add PIC to Lysis Buffer: this is the complete Lysis Buffer tL1. 
2. Add Lysis Buffer tL1 to the cells: use 25µl of complete Lysis Buffer tL1 every 
100,000 cells. 
3. Agitate manually the bottom of the tube to resuspend the cells and allow 
bubbles to form. 
4. Incubate on ice for 5’. 
5. Add HBSS + PIC to the cell lysate: use 75µl of HBSS + PIC every 100,000 
cells. 
 32 
6. Dispense 100µl of cell lysate in Covaris AFA microtubes. Make sure there 
are no precipitates before splitting cell lysate in Covaris microtubes, 
otherwise gently heat until crystals disappear. 
7. Sonicate samples using COVARIS S2 with the settings described in the 
dedicated section. 
8. After sonication, transfer the sheared chromatin to a new 1.5ml LoBind 
Eppendorf tube. 
9. Centrifuge 14,000rcf 10’ 4°C and collect supernatant in a new 1.5ml LoBind 
tube. 
10. Snap-freeze the chromatin and analyse chromatin shearing using 50µl of the 
sheared cells: 
a. transfer 50µl of the cell lysate to a new 1.5ml LoBind tube, add 5M 
NaCl to 250mM final concentration; 
b. incubate 4h at 65°C; 
c. perform standard phenol:chloroform DNA extraction and 
isopropanol/salts DNA concentration; 
d. analyse chromatin shearing on a 2% 0.5X TBE agarose gel 
electrophoresis. 
11. The sheared chromatin can be used immediately in ChIP or, if desired, it 
can be snap-frozen and stored at -20°C for up to 2 months. 
Magnetic immunoprecipitation 
1. Prepare the complete ChIP buffer tC1 by adding protease inhibitor complex 
to ChIP Buffer tC1. 
2. Add 100µl of complete ChIP buffer tC1 per 100µl of sheared chromatin. 
3. Add 200µl of diluted sheared chromatin per tube for each IP. 
4. Add antibodies: 
H3K27me3  1µg 
H3K9ac  1µg 
H3K4me3  1µg 
Normal IgG Rabbit 2µg 
5. Incubate 16h 4°C on a rotating wheel (40rpm). 
6. After the 16h-incubation prepare magnetic beads. Each IP requires 11µl of 
beads. 
a. Add 55µl of Beads Wash Buffer tBW1 to 11µl stock solution of 
beads for each IP and scale accordingly; 
b. Resuspend the beads and place them in a magnetic rack; 
c. Repeat the previous two steps once; 
d. Resuspend the bead pellet in 11µl of Beads Wash Buffer tBW1 per 
IP reaction. 
7. Add 10µl of prewashed Protein A-coated beads to each IP tube. 
8. Incubate the IP tubes for 2h on a rotating wheel (40rpm) at 4°C. 
9. Briefly spin the tubes and place them in the magnetic rack. 
10. Wait for 1’ and remove the supernatant. 
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11. Wash the beads with Wash Buffer tW1: 
a. add 100µl of Wash Buffer tW1 and gently shake the tubes to 
resuspend the beads; 
b. incubate 4’ on a rotating wheel at 4°C. 
12. Wash the beads with Wash Buffer tW2 following the procedure described 
for Wash Buffer tW1. 
13. Wash the beads with Wash Buffer tW3 in the same way. 
14. Wash the beads with Wash Buffer tW4 in the same way. 
DNA decrosslinking and purification 
1. After removing the last wash buffer, add 400µl of Elution Buffer tE1 to the 
beads and incubate for 30’ on a rotating wheel at RT. 
2. Briefly spin the tubes and place them in the magnetic rack for 2 minutes. 
3. Transfer the supernatant to a new tube and add to this supernatant 16µl of 
Elution Buffer tE2. 
4. Incubate for 4h in a thermomixer at 1,300rpm at 65°C. 
5. Briefly spin the tubes. 
6. Add 400µl of phenol:chloroform:isoamyl alcohol 25:24:1 to each sample 
and mix by vortexing. 
7. Centrifuge samples 10’ 14,000rcf RT, and transfer the upper aqueous 
phase into new 1.5ml LoBind Eppendorf tubes. 
8. Precipitate the DNA by adding 40µl of Precipitant tP1, 2µl of co-precipitant 
tCP2 and 1ml of ice-cold absolute ethanol to the samples. 
9. Vortex and incubate at -20°C for 16h. 
10. Centrifuge 25’ 14,000rcf 4°, remove the supernatant and add 1ml of ice-
cold 70% ethanol to the pellet. 
11. Centrifuge 10’ 14,000rcf 4°C, remove the supernatant and leave the tubes 
to air-dry 
12. Resuspend the pellet in 20µl of Low TE buffer. That corresponds to the 
purified immunoprecipitated DNA. 
13. Quantitate the DNA using the Qubit® fluorometer. 
SOLiD Fragment Library construction 
DNA end repair 
1. For each immunoprecipitated DNA, prepare the reaction mix in a 1.5ml 
LoBind Eppendorf tube: 
ChIP DNA   18µl 
5X Reaction Buffer  10µl 
10mM dNTP Mix  2µl 
End Polishing Enzyme 1 0.5µl 
End Polishing Enzyme 2 4µl 
Nuclease-free H2O  15.5µl 
_________________________________ 
Total    50µl 
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2. Vortex briefly, pulse-spin and incubate at room temperature for 30’. 
3. Purify the end repaired DNA using 1.8 volumes of Agencourt® AMPure® XP 
beads. Elute in 30µl of Low TE buffer. 
P1 and P2 adaptors ligation 
1. Dilute the P1 and P2 adaptors 1:20 in nuclease-free water [2.5pmol/µl]. 
2. Prepare the reaction mix: 
P1 Adaptor [2.5pmol/µl]  1µl 
P2 Barcoded Adaptor [2.5pmol/µl] 1µl 
5X T4 Ligase Buffer   20µl 
End-repaired DNA   30µl 
T4 DNA ligase [5U/µl]   5µl 
Nuclease-free water   43µl 
_______________________________________ 
Total     100µl 
3. Incubate 10’ RT. 
4. Purify the end repaired DNA using 1.8 volumes of Agencourt® AMPure® XP 
beads. Elute in 20µl of Low TE buffer. 
Nick Translation and library amplification 
1. For each sample prepare the reaction mix: 
Platinum® PCR Amplification Mix 100µl 
Library PCR Primer 1 [50µM]  2.5µl 
Library PCR Primer 2 [50µM]  2.5µl 
Adaptor-Ligated DNA   20µl 
_______________________________________ 
Total     125µl 
2. Divide the mix into two separate PCR tubes (125µl each) and run the 
following program in a thermal cycler: 
72°C 20’ 
95°C 5’ 
 
95°C 15” 
62°C 15”            x15 times 
70°C 1’ 
 
70°C 5’ 
4°C hold 
3. After amplification, combine the samples in one 1.5ml LoBind tube. 
4. Purify the amplified DNA with 1.8 volumes of Agencourt® AMPure® XP 
beads. Elute in 30µl of Low TE Buffer. 
5. Quantitate the amplified library using Qubit® fluorometer. 
6. Assess the quality of the library using Agilent Bioanalyzer. 
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Native ChIP on CHQ5B 
Cell lysis and nuclei purification 
2 x 106 cells were used for chromatin preparation, and 1 x 106 cells where then 
used for each immunoprepcipitation experiment. 
1. Resuspend cells in 1ml of PBS and transfer the sample in a 2ml eppendorf 
tube. 
2. Centrifuge 600rcf 10’, then discard the supernatant. 
3. Resuspend cell pellet completely in 1ml of ice-cold nChIP Buffer1 [0.3M 
sucrose, 5mM Na Butyrate, 0.1mM PMSF, 0.5mM DTT, 60mM KCl, 15mM 
NaCl, 5mM MgCl2, 0.1mM EDTA, 15mM Tris/Cl pH 7.5]. 
NOTE: cells must be in a single cell suspension. 
4. Add 1ml nChIP Buffer 2 and homogenize on ice in a Dounce homegeniser 
for 3minutes (90 strokes) using the pestle A. 
5. Incubate on ice in the Dounce homogeniser for other 7 minutes (no more 
than 7minutes). 
6. During the 7-minute incubation fill 8ml nChIP Buffer 3 into a 15ml Falcon 
tube (use 2 Falcon tubes for each sample). 
7. After the 7-minute incubation, overlay the 8ml nChIP Buffer 3 with 1ml cell 
suspension. Disturb the interface between nChIP Buffer 3 and cell 
suspension with the pipette tip. 
8. Centrifuge 3,500rcf 4°C 30’ in a swing-out rotor. 
9. Remove the supernatant carefully and completely. Pay attention not to 
touch the pellet. 
MNase chromatin digestion 
1. Resuspend the two nuclei pellets for each sample in 1ml MNase digestion 
buffer and aliquot 500µl of this suspension into two 1.5ml microcentrifuge 
tubes. 
2. Add 15U of MNase and incubate 5’ at 37°C. 
3. Stop the reaction by adding 20µl 0.5M EDTA to each 500µl MNase 
digested sample and put the tube on ice. 
4. Centrifuge 13,000rcf 10’ 4°C. 
5. Transfer the supernatant to a new tube (S1). 
6. Quantify chromatin in S1 by measuring OD260 against MNase digestion 
buffer (OD260=1 => [DNA]= 50ng/µl). Since lot of protein is present in the 
solution, this DNA quantification is not precise, but is sufficient for 
reproducibility. 
CHECKPOINT: phenol:chloroform DNA extraction from a 50µl aliquot of S1 
and gel electrophoresis of 20µl of this extract in a 2% 0.5X TBE agarose gel 
to verify the digestion. Expected result: mono–pentanucleosomes. 
STOPPING POINT (optional): S1 can be stored over night at -20°C. 
7. Prepare a 2% 0.5X TBE agarose gel. 
8. Thaw S1 and centrifuge 13,000rcf 10’ 4°C. 
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9. Transfer the supernatant in a new 1.5ml Eppendorf tube. 
10. Centrifuge 13,000rcf 10’ 4°C and transfer the supernatant in a new 1.5ml 
Eppendorf tube. 
11. Centrifuge 13,000rcf 10’ 4°C and transfer the supernatant in a new 1.5ml 
Eppendorf tube. These triple centrifugations are important to reduce the 
aspecific immunoprecipitation background. If a pellet is still visible after the 
third centrifugation, centrifuge again. 
12. Use 50µl of S1 for a phenol/chloroform extracted DNA and load 20µl on the 
gel (95V, 30’). Mono to pentanucleosomes should be visible. 
Incubation with the antibody 
400µl of the sample are used for each immunoprecipitation: one ChIP uses the 
H3K9me3 and another one uses a normal mouse IgG as a control. 
1. Add appropriate amounts of stock solutions to generate the antibody nChIP 
Incubation Buffer (150mM NaCl, 20mM Na Butyrate, 5mM EDTA, 0.2mM 
PMSF, 20mM Tris/Cl pH 7.4). Final volume is 1ml for each 
immunoprecipitation sample. Take into consideration the volume of S1 (in 
this case 400µl) and its buffer. 
2. Dilute S1 in 1ml final volume of nChIP incubation buffer. 
3. Add 2µg of antibody (2µg H3K9me3 in the sample tube, 2µg of normal 
mouse IgG in the control tube). 
4. Incubate overnight on a slowly rotating wheel at 4°C. 
Immunoprecipitation and DNA extraction 
1. Prepare 50µl of sepharose protein A + sepharose protein G (25µl sepharose 
protein A + 25µl sepharose protein G) for each sample. 
2. Wash the beads: 
3. Short spin; 
4. Carefully remove the supernatant; 
5. Replace the supernatant with an equal volume of sterile H2O; 
6. Add 50µl of the mixed sepharose protein A + G to each tube. 
7. Incubate for 5 hours at 4°C on a slowly rotating wheel. 
8. Prepare nChIP washing buffers (10ml of each buffer for each sample, 
including the control without antibody) and cool down to 4°C. 
9. After the 5h-incubation, centrifuge the chromatin-antibody-beads mixture 
10’ 4°C 11,600rcf. 
10. Keep the supernatant in a 2ml LoBind tube (this is the unbound fraction). 
11. Resuspend the pellet in 1ml nChIP Washing buffer 1 and transfer into a 
15ml Falcon tube containing 9ml nChIP washing buffer 1. 
12. Mix for 10’ on a rotating wheel at 4°C. 
13. Centrifuge 10’ 4,000rcf 4°C and pour off supernatant. 
14. Add 10ml nChIP washing buffer 2, mix for 10’ on a rotating wheel at 4°C 
and centrifuge 10’ 4,000rcf 4°C. 
15. Pour off supernatant. 
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16. Add 10ml nChIP washing buffer 3, mix for 10 min on a rotating wheel at 
4°C, and centrifuge 10’ 4,000 rpm 4°C. 
17. Pour off supernatant. 
18. Centrifuge 10’ 4,000rcf 4°C. 
19. Remove remaining supernatant completely. 
20. Resuspend pellet in 500µl nChIP elution buffer at room temperature. 
21. Transfer to a 1.5ml LoBind tube and incubate 15’ RT on a rotating wheel. 
22. Centrifuge 10’ 11,600rcf 20°C. 
23. Transfer the supernatant to a new 1.5ml LoBind tube. This is the bound 
fraction. 
DNA extraction 
Use a standard phenol/chloroform DNA extraction. Briefly: 
1. Add an equal volume of Phenol TE saturated pH 10.5. Mix by inversion and 
centrifuge 16,100rcf RT 5’. 
2. Transfer the aqueous phase into a new microcentrifuge tube, add an equal 
volume of Chloroform, and mix by inversion. Centrifuge 16,100rcf RT 5’. 
3. Repeat the previous step. 
4. Transfer the aqueous phase into a new LoBind 1.5ml microcentrifuge tube. 
5. Add 4µl of a 5µg/µl glycogen stock solution. 
6. Add 5M NaCl to 250mM final concentration, and add 1 volume isopropanol. 
7. Incubate 12-16h at -20°C. 
8. Precipitate by centrifugation: 30’ 16,100rcf 4°C and wash the pellet twice 
with 70% ethanol. 
9. Dry the pellet and resuspend in 20µl 10mM Tris/Cl pH 7.4. 
10. Quantitate the DNA using the Qubit® 2.0 fluorometer (DNA HS kit). 
Ion Proton low input protocol 
The nChIP on 1million cells yielded 2ng of immunoprecipitated DNA. This DNA is 
quite heterogeneous in its dimensions: in fact it shows a nucleosome-ladder 
pattern. To prepare a sequencing library, the DNA needs to be sonicated in order to 
bring the average DNA fragment size to approximately 170bp. 
All the Buffer and enzymes used here are part of the Ion Proton Fragment Library 
Preparation kit. 
1. Sonicate the nChIP immunoprecipitated DNA using the covaris conditions 
described in the section “Fragmentation of the nChIP DNA for Ion Proton 
fragment library preparation”. 
2. End-repair the sonicated DNA fragments. In a 1.5ml LoBind tube mix: 
1-10ng di ChIP DNA  ~50-79µl 
H2O    to 79µl 
5X End Repair Buffer  20µl 
End Repair Enzyme  1µl 
_________________________________ 
Total    100µl 
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3. Mix well by pipetting and incubate RT for 20’. 
4. Purify the End-Repaired DNA with 1.8 volumes of Agencourt® AMPure® XP 
beads and elute in 25µl of Low TE buffer. 
 
Barcoded adapters ligation 
1. Dilute 1:16 both Ion P1 Adapter and Barcoded adapters in H2O. 
2. In a 0.2ml PCR tube prepare the ligation mixture. Add the reagents in the 
order reporter below: 
End-repaired ChIP DNA 25µl 
10X Ligase Buffer  10µl 
Ion P1 adapter, 1:16  1µl 
Ion Barcode adapter 1:16 1µl 
dNTP mix   2µl 
H2O    51µl 
DNA ligase   2µl 
Nick repair Polymerase 8µl 
________________________________ 
Total    100µl 
3. Incubate samples in a thermal cycler with the following program: 
25°C 15’ 
72°C 5’ 
4°C Hold (it is not a stopping point: proceed as soon as 
possible with purification and size selection) 
4. Purify the adapter-ligated DNA using 1.8volumes of Agencourt® AMPure® 
XP beads. Elute in 25µl of Low TE buffer. 
Library amplification 
1. Prepare the library amplification mixture as follows (recipe for 1 sample): 
Platinum® PCR SuperMix High Fidelity 100µl 
Library Amplification Primer Mix  5µl 
ChIP DNA     25µl 
_________________________________________ 
Total      130µl 
2. Split the 130µl-reaction volume in two 0.2ml PCR tube and run the following 
program on a thermal cycler: 
95°C 5’ 
 
95°C 15” 
62°C 15”            x15 times 
70°C 1’ 
 
70°C 5’ 
4°C hold 
3. Collect the same sample in a unique 1.5ml LoBind tube 
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4. Purify the amplified library with 1.5 volumes of AMPure® XP beads and 
elute in 50µl of Low TE buffer. 
5. Purify the library another time with 1.5 volumes of AMPure® XP beads and 
elute in 25µl of Low TE buffer. 
6. Quantitate the DNA using the Qubit® fluorometer and assess the library 
quality on Agilent Bioanalyzer. 
 
 
DNA methylation 
Sodium Bisulfite DNA conversion 
Bisulphite conversion of the genomic DNA was conducted using the EZ DNA 
Methylation-Lightning™ Kit (Zymo Research, Irvine, CA) following manufacturer's 
instructions. 
1. Dilute 1µg of NanoDrop™-quantified DNA in 20µl of water. 
2. Add 130µl of Lightnin Conversion Reagent to the 20µl of DNA from the 
previous step in a 0.2ml PCR tube. 
3. Mix by pipetting and spin to ensure no droplets are present on the surface 
of the tube. 
4. Place the PCR tube in a thermal cycler with the program: 98°C for 8’, 54°C 
for 60’ and 4°C up to 20h. 
5. Add 600µl of M-Binding Buffer to a Zymo-Spin™ IC Column and place it 
into a provided Collection Tube. 
6. Load the 150µl sample (after the thermal cycler step) into the M-Binding 
Buffer containing column. Close the cap and mix by inverting the tube 
several times. 
7. Centrifuge 15,000rcf 30” RT, then discard the flow-through. 
8. Add 100µl of M-Wash Buffer to the column. 
9. Centrifuge 15,000rcf 1’ RT. 
10. Add 200µl of L-Desulphonation Buffer to the column close the cap and 
incubate RT for 20’. After the incubation centrifuge 15,000g RT 1’. 
11. Add 200µl M-Wash Buffer to the column, then centrifuge 15,000rcf 30” RT. 
Repeat this wash step. 
12. Let the column stand at RT for 2’. 
13. Place the column on a new 1.5ml microcentrifuge tube and add 10µl M-
Elution Buffer to the column matrix. 
14. Incubate RT for 2’, then centrifuge for 1’ at 15,000rcf 
15. Add other 10µl of Elution buffer directly to the column matrix and incubate 
RT for 2’. 
16. Centrifuge 15,000rcf 1’ RT to elute the DNA. 
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A preliminary protocol: MeSS v1 
Adapter sequences for this protocol: 
Oligo P1 UP: 
5'–CCACTACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGA–3’ 
 
Oligo P1 DOWN 
5'–
NNNNNNTCACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTAGTGGC
C–3’ 
 
Oligo P2 UP 
5’–(P)AGAGAATGAGGAACCCGGGGCAGTT–3’ 
 
Oligo P2 DOWN 
5’–CTGCCCCGGGTTCCTCATTCTCTNNNNNN–3’ 
 
Protocol 
1. Bisulfite-treat 1µg of DNA. 
2. Sonicate the bisulfite treated DNA as specified in the dedicated Covaris 
section. 
3. In a 0.2ml PCR tube mix: 
Bisulfite-treated and sonicated DNA  500ng in 6.4µl 
10X T4 DNA ligase buffer   0.8µl 
T4 Polynucleotide kinase [10U/µl]  0.8µl 
_____________________________________________________ 
Total      8µl 
4. Incubate the following program in a pre-heated thermal cycler: 
37°C 30’ 
65°C 20’ 
65°C Hold 
 
During the 65°C-hold phase add 1µl of “P1 adapter” and 1µl of “P2 adapter”. Mix 
well by pipetting. These adapters were obtained by mixing100µM Oligo (P1 or P2) 
UP and 100µM Oligo (P1 or P2) DOWN in a 1:5 ratio. 
 
5. Incubate 65°C 10’ and immediately put on ice for 5’. 
6. Incubate at 16°C for 10’ and, in the meanwhile, prepare the ligation mixture: 
10X T4 DNA ligase buffer 1µl 
10mM ATP   1µl 
T4 DNA ligase [10U/µl] 7µl 
40% PEG8000 
_______________________________ 
Total    10µl 
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Since PEG8000 greatly increases the viscosity of the mixture, mix by 
pipetting several times. 
7. After the 10’ incubation add the ligation mixture and incubate at 16°C for 
16h. 
8. Add 0.66µl of 10 mM dNTPs mix and 0.5µl of E.coli DNA Polymerase 
Klenow fragment (5U/µl). 
9. Incubate at 25°C for 30’. 
10. Purify the sample twice with 1.8 volumes of Agencourt® AMPure® XP 
beads. Elute in 20µl of Low TE buffer. 
11. Incubate in a thermal cycler with the following program: 
95°C 5’ 
 
95°C 15” 
62°C 15”              x15 times 
70°C 1’ 
 
70°C 5’ 
4°C hold 
12. Purify the sample using 1.5 volumes of Agencourt® AMPure® XP beads.  
13. Elute in 20µl Low TE buffer. 
14. Quantitate the DNA using the Qubit® fluorometer and assess the library 
quality with Agilent Bioanalyzer. 
The definitive protocol: MeSS v2 
300ng of Mb NanoDrop™-quantified Mb DNA were sonicated and then bisulfite-
treated. 
Adapters: 
 
MeSS blocked P2: 
5' -
CTGCCCCGGGTTCCTCATTCTCTGTGTAAGAGGCTGCTGTACGGCCAAG
GCGTNNNNNN-(P) - 3' 
 
Oligo P1 UP: 
5'–CCACTACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGA–3’ 
 
Oligo P1 DOWN 
5'–
NNNNNNTCACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTAGTGGC
C–3’ 
 
Template phosphorylation 
1. Prepare the reaction mix in a 0.2ml PCR tube: 
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300ng DNA   15µl 
T4 DNA ligase (Invitrogen) 4µl 
PNK (NEB)   1µl 
____________________________ 
Total    20µl 
2. Mix well by pipetting and pulse-spin. 
3. Incubate in a thermal cycler with heated lid with the following program: 
22.5°C  30’ 
80°C  20’ 
4°C  Hold 
Oligonucleotide hybridization for template switching 
1. Add to the previous reaction tube: 
i. 50µM MeSS Blocked P2 1µl 
ii. 10mM dNTPs   1.5µl 
iii. NEB Buffer 2   1µl 
iv. H2O    5.5µl 
v. _______________________________ 
vi. Total    29µl 
2. Incubate for 5’ at 90°C in a thermal cycler, and then put immediately on ice 
for 5’. 
Template switching 
1. Add to the previous reaction tube: 
DNA polymerase I (NEB) 1µl 
____________________________ 
Total    30µl 
2. Incubate in a thermal cycler with the following program: 
16°C 30’ 
80°C 5’ 
3. Transfer the sample in a 1.5ml LoBind tube. 
4. Purify the sample using 1.5 volumes of Agencourt® AMPure® XP beads. 
Elute in 30µl of H2O. 
P1 adapter hybridization and ligation 
1. Prepare the hybridization mix in a 0.2ml PCR tube: 
DNA from previous step 30µl 
50µM MeSS P1 UP  1µl 
50µM MeSS P1 DOWN 1µl 
H2O    6µl 
____________________________ 
Total    38µl 
2. Incubate in a thermal cycler for 5’ at 90°C, then put immediately on ice for 
5’. 
3. Add to the previous tube: 
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5X T4 DNA ligase buffer (Invitrogen)  10µl 
DNA ligase [5U/µl]    2µl 
_________________________________________ 
Total      50µl 
4. Incubate 16h in a thermal cycler without heated lid. 
5. Inactivate the ligase for 20’ at 80°C in a thermal cycler. 
6. Purify the adapter-ligated DNA with 1.5 volumes of Agencourt® AMPure® 
XP beads. Elute in 50µl H2O. 
7. Purify again the sample with 1.5 volumes of Agencourt® AMPure® XP 
beads. Elute in 20µl H2O. 
Library amplification PCR 
1. Prepare the amplification mix: 
5X GoTaq Buffer  4µl 
10mM dNTPs   0.4µl 
50µM SOLiD PCR Primer 1 0.5µl 
50µM SOLiD PCR Primer 2 0.5µl 
DNA    14.4µl 
GoTaq2 [5U/µl]  0.2µl 
______________________________ 
Total    20µl 
2. Incubate in a thermal cycler with the following program: 
95°C 5’ 
 
95°C 15” 
62°C 15”              x15 times 
70°C 1’ 
 
70°C 5’ 
4°C hold 
 
3. Purify the sample using 1.5 volumes of Agencourt® AMPure® XP beads. 
Elute in 20µl Low TE buffer. 
4. Repeat the previous step once. 
5. Quantitate the DNA using the Qubit® fluorometer and assess the library 
quality with Agilent Bioanalyzer. 
 
SureSelect Methyl-Seq Target enrichment 
The kit is a target enrichment system, which can be used to focus on regions where 
methylation is known to impact gene regulation. It can target CpG islands, DNaseI 
hypersensitive sites and can reveal methylated regions that are not able to be 
detected by reduced representation bisulfite sequencing (RRBS), and the 
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enrichment-based technique of methylated DNA immunoprecipitation sequencing 
(MeDIP-seq). 
 
For this kit I used the DNA of 2 Mb samples (at division 34.5 and 36) and 2 Mt 
samples (9 days of differentiation). 
Before starting the integrity of the starting DNA was evaluated on a 0.6% agarose 
gel electrophoresis in 1X TAE buffer. 
Assess the quality of the DNA using NanoDrop™ 1000 (Thermo Scientific, 
Waltham, MA): the ratio A260/A280 should be between 1.8 and 2. 
Quantitate the DNA using the Qubit® 2.0 fluorometer (Invitrogen, Life Technologies, 
Carlsbad, CA). 
Protocol 
DNA shearing 
1. Shear the DNA following the instruction reported in “1. Covaris 
sonication of the DNA before bisulfite treatment”. 
2. After shearing quantitate the DNA using Qubit® fluorometer (DNA HS kit): 
proceed with no less than 2µg of DNA for next steps. 
3. Agilent 2100 BioAnalyzer to check the sonication (Agilent Technologies). 
DNA HS kit. 
Repair the DNA ends 
We proceed using 3µg of DNA in 50µl Low TE (desiccate the sample in a Speed 
Vac  to reach this concentration). 
1. Add 50µl of XT2 End-Repair Master Mix to the sample (on ice) and mix well 
by pipetting. 
2. Incubate in the thermal cycler at 20°C for 30’. Do not use heated lid. 
3. Purify sample using 1.8 volumes of Agencourt® AMPure® XP beads and 
elute the samples in 22µl of H2O. 
Adenylate the 3’end of the DNA fragments 
1. 20µl of End-repaired DNA + 20µl of dA-tailing Master Mix. 
2. Incubate 30’ at 37°C in a thermal cycler. Do not use heated lid. 
Ligate the methylated adapters 
3. transfer the dA-tailed fragments ON ICE and add 5µl of XT2 Ligation Master 
Mix. 
4. Add 5µl of SureSelect Methyl-Seq methylated Adaptor and mix by pipetting. 
5. Incubate in a thermal cycler for 15’ (no more than 15’) at 20°C. Do not use 
heated lid. 
6. Purify the adaptor ligated DNA using 1.2 volumes of Agencourt® AMPure® 
XP beads. Elute in 22µl H2O. 
7. Quantitate the DNA using Qubit® fluorometer. To proceed it is necessary to 
have, at least, 500ng of adaptor-ligated DNA. 
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Hybridization 
1. Dry the sample in order to have a total volume of 3.4µl. After drying, vortex 
to recover even the DNA on the walls of the tube, then spin for 10”. 
2. Prepare the Hybridization Buffer in a PCR tube and store it RT. 
SureSelect Hyb#1 25µl 
SureSelect Hyb#2 1µl 
SureSelect Hyb#3 10µl 
SureSelect Hyb#4 13µl 
_______________________ 
Total   49µl 
If a precipitate forms, warm the solution for 5’ at 65°C. 
3. Prepare the SureSelect Methyl-Seq Block Mix in a PCR tube and keep it on 
ice. 
SureSelect Indexing Block#1  2.5µl 
SureSelect Block#2   2.5µl 
SureSelect Methyl-Seq Block#3 0.6µl 
__________________________________ 
Total     5.6µl 
4. Prepare the RNase block in a PCR tube and keep it on ice. 
RNase block  0.5µl 
H2O   1.5µl 
_______________________ 
Total   2µl 
5. In the RNase block tube add 5µl of SureSelect Human Methyl-Seq Capture 
Library. Mix well by pipetting. 
6. In the SureSelect Methyl-Seq Block Mix tube add the 3.4µl of the library. 
Mix well by pipetting. 
7. Put the SureSelect Methyl-Seq Block + library tube in a thermal cycler with 
the following program (heated lid set at 105°C). 
95°C 5’ 
65°C hold 
At the end of the program open the lid, but don’t remove the tube: it must 
stay at 65°C. 
8. Put the Hybridization Buffer tube in the thermal cycler at 65°C and incubate 
for 5’. 
9. After the 5’-incubation put the RNase block + Capture Library tube at 65°C 
in the thermal cycler. 
10. Incubate all of the tubes at 65°C in the thermal cycler for 2’ and, even after 
these 2’, do not remove tubes from the thermal cycler. 
11. Transfer 13µl of Hybridization Buffer in the RNase block + Capture Library 
tube. 
12. Transfer the 9µl of the library tube in the RNAse + Capture + Hybr tube and 
mix by pipetting 8-10 times. At this point the volume of the hybridization 
mixture is 27-29µl. 
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13. Seal the caps and incubate for 24h at 65°C in the thermal cycler with 
heated lid at 105°C. 
Prepare the streptavidin beads 
1. Set the water bath at 65°C and pre-warm the SureSelect Wash Buffer #2 at 
65°C. 
2. Vortex the Streptavidin beads (Dynabeads C1, Life technologies) and 
prepare 50µl of beads for each sample in a 1.5ml eppendorf tube. 
3. Wash the beads: 
4. add 200µl of SureSelect binding buffer; 
5. vortex for 5” and spin; 
6. put on a magnetic rack till the solution clarify; 
7. remove and discard SN. 
8. Repeat the washing step two other times (for a total of three washes). 
9. Resuspend the beads in 200µl of SureSelect Binding Buffer. 
Capture hybrids using streptavidin beads 
1. At the end of the 24h-incubation, measure and register the remaining 
volume of the reaction. 
2. Keep the tube at 65°C while adding the reaction volume directly from the 
thermal cycler to the streptavidin beads solution. 
3. Incubate on a wheel rotator at RT for 30’ (22rpm), then pulse-spin and 
magnetize. Remove the supernatant. 
4. Resuspend the beads in 500µl of SureSelect Wash Buffer #1 by vortexing 
for 5” and incubate RT for 15’, then magnetize and remove the supernatant. 
5. Wash the beads: 
a. resuspend the beads in 500µl of SureSelect Wash Buffer #2 and 
vortex for 5”; 
b. incubate 10’ in the water bath at 65°C; 
c. spin and magnetize; 
d. remove the supernatant. 
6. Repeat the washing step two other times, for a total of 3 washes. Make 
sure the entire wash buffer has been removed. 
7. Mix the beads in 20µl of SureSelect Elution Buffer on a vortex mixer for 5” to 
resuspend the beads and incubate the sample for 20’ RT. 
8. Magnetize and transfer the SN to a new 1.5ml LoBind Eppendorf tube. 
Discard the beads. 
9. Proceed immediately to bisulfite conversion. 
Bisulfite conversion 
EZ DNA Methylation-Lightning kit was used as previously described. Avoid the first 
denaturation step. Briefly: 
1. Transfer 130µl of Lightning conversion reagent in a PCR tube. 
2. Add 20µl of the eluted captured library and mix by pipetting. 
3. Thermal cycler: 
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54°C 60’ 
4°C hold 
4. Follow manufacturer’s instructions for desulfonation and purification. 
5. For the elution: 
a. put the column into a new 1.5ml eppendorf tube and let the tubes 
stand at RT for 2’ before proceeding; 
b. add 10µl of M-elution buffer directly to the column matrix and 
incubate RT for 3’; 
c. centrifuge 60” 13,000rcf; 
d. add other 10µl M-elution buffer to the column matrix and incubate 
RT for 3’; 
e. centrifuge 60” 13,000rcf. 
6. The final volume is ~ 20µl. 
PCR amplification of the bisulfite-treated libraries 
1. Prepare the reaction mix: 
H2O    30µl 
SureSelect 2X Taq2000 50µl 
MethySeq PCR Primer F 1µl 
MethySeq PCR Primer R 1µl 
_____________________________ 
Total    82µl 
2. Add 18µl of the converted DNA. Mix well by pipetting. 
3. Thermal cycler: 
95°C 2’ 
 
95°C 30” 
60°C 30”            x10 
72°C 30” 
 
72°C 7’ 
4°C hold 
4. Purify the PCR product using 1.8 volumes of Agencourt ® AMPure® XP 
beads. Elute in 25µl of H2O. 
Sample indexing 
1. In a 0.2ml PCR tube prepare the PCR mix (for 1 sample): 
SureSelect Methyl-Seq 2X Taq2000 MM  25µl 
SureSelect Methyl-Seq indexing primer common 0.5µl 
PCR primer Index of choice    0.5µl 
Amplified bisulfite-treated library   24µl 
___________________________________________________ 
Total       50µl 
2. Mix well by pipetting and incubate in a thermal cycler with the following 
program: 
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95°C 2’ 
 
95°C 30” 
60°C 30”            x6
72°C 30” 
 
72°C 7’ 
4°C hold 
 
3. Purify the indexed libraries using 1.8 volumes of Agencourt® AMPure® XP 
beads. Elute in 24µl of H2O 
4. Quantitate the DNA using the Qubit® fluorometer. 
5. Assess the quality of the library with the Agilent bioanalyzer. 
6. Mix the sample in order to have 15µl of a 5nM sequencing pool. 
7. Bridge PCR and Illumina® HiSeq1000 Sequencing reactions were 
performed by the sequencing service of the University of Verona (Prof. Delle 
Donne Group). 
Ion Proton BS-seq 
After Bisulfite conversion the DNA was treated as follows. 
Second strand synthesis 
1. Prepare the reaction mix: 
Bisulfite-treated DNA   200ng in 10µl 
10 mM dNTPs    1µl 
10X NEBuffer 2   2µl 
100µM Random Hexamer Primers 2µl 
Nuclease-free Water   3µl 
______________________________________ 
Total     18µl 
2. Incubate the mix in a thermal cycler with the following program: 
75°C 5’ 
5°C 10’ During this 10’ 5°C incubation add 2µl of E. coli 
DNAPolymerase I (NEB, 10U/µl) 
25°C 10’ 
37°C 10’ 
75°C 20’ 
12°C ∞ 
At the end of the program the DNA is double stranded, blunt ended, but 
unphosphorylated.  
3. Purify the dsDNA with 1.5 volumes of Agencourt® AMPure® XP beads. Elute 
in 20µl of Low TE. 
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4. Transfer the supernatant in a new 1.5ml LoBind tube without disturbing the 
pellet. 
Library construction protocol 
End-repair of the DNA 
1. Prepare the end-repair mix in a 1.5ml LoBind tube: 
dsDNA    20µl 
H2O    59µl 
5X End-Repair Buffer  20µl 
End Repair Enzyme Mix 1µl 
________________________________ 
Total    100µl 
2. Mix well by pipetting and incubate RT for 20’. 
Agencourt® AMPure® XP beads size selection 
Two rounds with different concentrations of beads are used to size-select the DNA. 
In the first round DNA >250bp is captured on the beads, and DNA ≤250bp is 
retained in the supernatant. In the second round DNA >100bp is captured from the 
first-round supernatant. The size-selected DNA is then 100-250bp in length. 
First round 
1. Add H2O to bring to 250µl the final volume of the DNA solution. 
2. Add 225µl (0.9 volumes) of Agencourt® AMPure® XP beads to the sample, 
mix by pipetting, then pulse-spin and incubate at RT for 5’ 
3. Pulse-spin and place the sample in a magnetic rack for 3’ 
4. Carefully transfer the supernatant to a new 1.5ml LoBind tube. Do not 
disturb the pellet 
Second round 
1. Add 100µl (0.2 volumes) of Agencourt® AMPure® XP beads to the 
supernatant from the first round, pipet to mix, and proceed as a normal 
Agencourt® AMPure® XP beads DNA purification. Elute in 25µl of Low TE 
buffer. 
Adapters ligation, nick-repair and ligated-DNA purification 
1. Prepare the reaction mix in a 0.2ml PCR tube: 
End-repaired DNA  25µl 
10X Ligase Buffer  10µl 
Proton adapters  2µl 
10mM dNTP Mix  2µl 
H2O    51µl 
DNA ligase   2µl 
Nick-repair polymerase 8µl 
_____________________________ 
Total    100µl 
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2. Incubate in a thermal cycler with the following program: 
25°C 15’ 
72°C 5’ 
4°C ∞ This is not a stopping point, proceed as soon 
as possible. 
 
3. Purify the sample using 1.4 volumes of Agencourt® AMPure® XP beads. 
Elute in 20µl of Low TE buffer. 
Library amplification 
1. Prepare the library amplification mixture as follows (recipe for 1 sample): 
Platinum® PCR SuperMix High Fidelity 100µl 
Library Amplification Primer Mix  5µl 
ChIP DNA     25µl 
_____________________________________________ 
Total      130µl 
2. Split the 130µl-reaction volume in two 0.2ml PCR tube and run the following 
program on a thermal cycler: 
95°C 5’ 
 
95°C 15” 
62°C 15”            x10 times 
70°C 1’ 
 
70°C 5’ 
4°C hold 
3. Collect the same sample in a unique 1.5ml LoBind tube. 
4. Purify the library with 1.4 volumes of AMPure® XP beads and elute in 20µl 
of Low TE buffer. 
5. Quantitate the DNA using the Qubit® 2.0 fluorometer and assess the quality 
of the library on the Agilent Bioanalyzer. 
The sequencing core of Prof. Valle Group performed emulsion PCR, beads 
enrichment and Ion Proton Sequencing. 
 
Bioinformatics analysis 
In advanced laboratory methodologies (HT-NGS) the need for a new generation of 
bioinformatic tools is an essential prerequisite to accommodate further strategic 
development and improvement of the output results. 
ChIP-seq analysis 
The sequencing reads produced were imported in CLC Genomics Workbench 6.5, 
a commercial software for DNA sequence analysis, and mapped against the 
reference genome (hg19) with the build in aligner. The uniquely aligned reads are 
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then used as input for the “ChIP Seq” analysis module of CLC, using default 
parameters. 
CLC allows to find regions that are enriched in the ChIP-sample to identify peaks of 
protein-DNA binding. 
Once the enriched regions are established, a threshold or minimum peak height is 
calculated based on the false discovery rate. The goal is to determine whether a 
region of enrichment, or peak, is significant over background. 
Experimental design, exhaustive antibody testing and careful sample preparation to 
minimize background are more critical to success of an experiment than the exact 
peak calling algorithm used for analysis. 
BS-seq 
After sequencing the bisulfite-treated DNA, the reads were aligned against the 
reference genome using PASS-bis software, which allow for mapping the reads 
tolerating the reduced complexity resulting from bisulfite treatment. Sequencing 
clonality has been removed from the mapping output using a PASS supplied 
module. Moreover, the set of tools of PASS-bis was even used to pair the paired-
end reads obtained with Illumina Sequencing. 
PASS-bis software (Campagna D et al., 2013) performed the methylation calling of 
CG, CHG and CHH locations along the genome or along selected regions. After 
this passage the MethylKit package (Akalin A, et al., 2012), written for the R CRAN 
statistics software, was used to discover the differentially methylated regions and 
sites of the Illumina sequenced samples. 
Data integration 
Data were annotated and integrated in pathways using DAVID 6.7 (Database for 
Annotation, Visualization and Integrated Discovery) webserver (Huang DW et al., 
Nature Protoc. 2009; Huang DW et al., Nucleic Acids Res. 2009), selecting the 
gene ontology and kegg pathways as data sources. Data were visualized in IGV 
(Robinson JT et al., 2011). 
Graphite web, a public web server for the analysis and visualization of biological 
pathways using high-throughput gene expression data, has been used to highlight 
relevant pathways in gene expression data. 
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Results and Discussion of the 
preliminary protocols 
Next Generation Sequencing represents a revolution in modern biology. Apart from 
genomics and transcriptomics, it is opening new opportunities also in the field of 
high-resolution genome-wide epigenetics. The continuous technology 
improvements and the concurrent cost reduction are now allowing in depth 
epigenomics investigations, thus unravelling chromatin state and rearrangements 
during cell life. The activation or repression of genes controlling human skeletal 
muscle differentiation requires an extensive crosstalk between transcription factors, 
DNA methylation and histone modifications. The exact sequence of chromatin 
events underlying myogenesis is far from being characterized, but a role for 
epigenetics both in preventing and maintaining myogenic terminal differentiation has 
been postulated. 
To investigate the epigenetic landscape of human adult myogenesis I was 
particularly interested in two methodological approaches: chromatin 
immunoprecipitation and DNA bisulfite treatment followed by deep sequencing 
(ChIP-seq and BS-seq).  
A difficulty in studying epigenetics comes from the novelty of most procedures and 
the consequent susceptibility of the methods to be very little reproducible; 
therefore, the experimental plan must be designed with great attention and the 
protocols must be carefully optimized on the specific experimental model. 
No techniques for studying epigenetics were available in the laboratory at the 
beginning of my PhD study, so I had to critically evaluate existing methods to 
decide if any were suitable for my research. All the methods required an extensive 
work of optimization, but sometimes, since this field of research is very new, there 
were no methods available and I had to challenge myself in the development of new 
techniques. 
The results I obtained during the first part of my PhD project are mainly negative 
results; nevertheless they were essential for the further development of my studies.  
Many technical problems made difficult the establishment of robust methods for 
ChIP-seq and BS-seq and this chapter summarizes step-by-step these 
developments. 
Chromatin Immunoprecipitation (ChIP) 
One of the best ways to take a comprehensive look at the epigenome is chromatin 
ChIP-seq, as it allows profiling the genome-wide distribution of a protein of interest. 
DNA-protein complexes can be isolated using highly specific antibodies, then the 
DNA fragments associated to the protein of interest are extracted and massively 
sequenced. 
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General guidelines for ChIP experiments recommend the optimization of the 
chromatin preparation procedure and the evaluation of antibody specificity; in fact, 
crosslinking and sonication conditions vary between cell types, and half of the ChIP-
grade antibodies are not able to recognize their antigen in chromatin (Egelhofer TA 
et al., 2011).  
Preliminary ChIP tests were conducted either on crosslinked or native chromatin, 
and the results are presented in this section with a brief discussion. 
Crosslinked ChIP (X-ChIP) 
Crosslinked ChIP is suitable for mapping proteins that are both weakly and strongly 
associated to the DNA as the crosslinking minimizes chromatin rearrangements 
during the experiment. An overview of a general XChIP-seq experiment is reported 
in Figure 2. After shearing the formaldehyde-crosslinked chromatin in 300–1,000bp-
long fragments, antibodies are used to enrich the proteins of interest by 
immunoprecipitation. Finally, the crosslinking is reverted and the DNA is isolated 
and sequenced. 
 
Figure 2| Standart outline of a crosslinked ChIP-seq experiment: cells are crosslinked with 
formaldehyde, which introduces covalent bonds between proteins and DNA. Chromatin is then 
fragmented in pieces suitable for immunoprecipitation and protein-DNA complexes of interest are 
isolated by the use of specific antibodies. DNA is then extracted and sequenced with next generation 
sequencing platforms. 
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Chromatin preparation: from mouse dissection to nuclei extraction. 
XChIP optimal conditions can be very different between cell types: the perfect 
balance between crosslinking and sonication is a prerequisite to perform good and 
reproducible experiments.  
Since different cell types can be more or less difficult to obtain, I firstly set up some 
preliminary steps on mouse splenocytes that were readily available from mice that 
had been sacrificed for other experiments. A further step of the optimization was 
done on C2C12 cells, a murine myoblast immortalized cell line that is easy to 
maintain in culture. Finally, the experiments were performed using CHQ5B cells, a 
primary myoblast cell culture derived from human muscle biopsies.  
Mice splenocytes: crosslinking and shearing 
Mice splenocytes were initially chosen to set-up the chromatin preparation method. 
An adult healthy mouse spleen contains about 100 million splenocytes that are 
adequate for 4-5 assays. Approximately 20million cells at a time were processed to 
set-up the chromatin preparation conditions and formaldehyde was chosen as 
crosslinking reagents due to the possibility of reversing crosslinks by heating the 
sample. 
Several conditions were tested in order to optimize the formaldehyde crosslinking 
reaction; in fact, both excessive and insufficient crosslinking impair the experiment 
through altering sonication efficiency and epitope exposure and abundance in the 
chromatin sample. 
Formaldehyde crosslinking, performed with 1% final concentration of formaldehyde 
in PBS, was optimized through a time-course experiment spanning from 5 to 30 
minutes. In parallel, several sonication conditions were tested for obtaining the best 
compromise between crosslinking and sonication conditions. At the end, the 
definitive protocol for the preparation of chromatin from mice splenocytes chromatin 
preparation contemplate 20’ PBS crosslinking with formaldehyde at 1% of final 
concentration, and 10’ sonication in 16×65mm COVARIS glass tubes with 
maximum settings at 4-8°C. Sonication results of mice splenocytes are reported in 
Figure 3. 
 
Figure 3| DNA from murine splenocytes after crosslinking and sonication. Lane 1: 1kb GeneRuler DNA 
ladder; Lane 2: DNA after crosslinking and 5’ of sonication; Lane 3: DNA after 10’ of sonication. 
2 31
2
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C2C12 crosslinking and shearing 
C2C12 is a murine myoblast cell line that has the ability to differentiate in low serum 
conditions and is a model for studying muscle differentiation in mammals. Since it is 
easier to obtain large numbers of murine rather than human myoblasts I chose to 
test chromatin preparation conditions using the C2C12 murine immortalized muscle 
cells before moving to the human model. The conditions used for splenocytes were 
inadequate for the new model, system so I repeated the time-course experiments 
and found new conditions: crosslinking was performed for 12min in DMEM + 10% 
FBS and 10million cells were sonicated at a time, for 8min with maximum settings 
of the power (Figure 4). 
 
 
 
Further experiments revealed that there were no significant differences in 
crosslinking cells in adhesion, or in suspension. 
CHQ5B: nuclei extraction before crosslinking 
Although C2C12 and CHQ5B are both similar in that they are myoblasts, chromatin 
preparation turned out to be significantly different. In fact, on applying to CHQ5B 
the crosslinking conditions used for C2C12, the chromatin appeared to be 
completely disrupted even before sonication (Figure 5). The attempts to improve 
this by modifying crosslinking time, buffer and temperature failed, the chromatin 
always appeared broken before sonication. 
 
Figure 4 | Agarose gel electrophoresis of C2C12 DNA after crosslinking and sonication: (left) 
myoblasts and (right) myotubes. 
Left: first lane 1kb GeneRuler DNA ladder, second lane C2C12 Mb DNA after sonication. 
Right: first lane LowRange DNA ladder, second lane C2C12 Mt DNA after 4’ sonication, third lane 
C2C12 Mt DNA after 8’sonication. 
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We hypothesized that this problem might be caused by the release of DNase from 
cytosolic components during the cell lysis step. To try to overcome this problem we 
isolated the nuclei before crosslinking and we found that the problem was solved 
(Figure 6).  
Chromatin preparation experiments were performed using 10 million cells at a time; 
nuclei were crosslinked with formaldehyde in PBS for 10min on ice + 5min at room 
temperature in PBS and sonicated for 8min at the maximum settings (Covaris 
sonicator). 
 
 
 
 
TBP and H3K9me3: immunoprecipitation and SOLiD™ sequencing 
Sheared chromatin from 5X 106 nuclei of both CHQ5B myoblasts (Mb) and 
myotubes (Mt) was immunoprecipitated with antibodies (3µg) to either TBP or 
Figure 5 | Agarose gel electrophoresis of CHQ5B Mb DNA (first lane) after 
whole-cell crosslinking, but before sonication. Notably the chromatin 
appeared to be disrupted before shearing. 1kb GeneRuler molecular 
weight marker is loaded in the second lane. 
Figure 6 | Agarose gel electrophoresis of CHQ5B Mb (second lane) and Mt (third lane) 
DNA after nuclei extraction and crosslinking and before sonication. 1kb GeneRuler DNA 
ladder is loades on the first lane. 
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H3K9me3. TBP (TATA-box Binding protein) specifically marks actively transcribed 
genes, whereas H3K9me3 is a marker of constitutive heterochromatin. 
Each immunoprecipitation yielded about 20ng of DNA (Mb TBP: 25.06ng, Mb 
H3K9me3: 21.48ng, Mt TBP: 14.20ng, Mt H3K9me3: 25.54ng). 
To test the specificity of the immunoprecipitation, an aliquot of the 
immunoprecipitated DNA was used for semi-quantitative PCR: accordingly to 
SOLiD™ protocol for ChIP-seq experiments, two primer pairs were chosen to 
quantitate and amplify an heterochromatic region (SAT2) and a constitutively 
expressed gene (FOS). With these antibodies we would expected to see enrichment 
in the SAT2 and FOS regions, respectively for the H3K9me3 and TBP 
immunoprecipitated sample. 
 
Figure 8 | Agarose gel electrophoresis of SAT2 semiquantitative PCR in Mb TB- and H3K9me3-
immunoprecipitated samples. SAT2 band becomes visible in the H3K9me3 immunoprecipitated 
sample at the 32nd PCR cycle. On the external left and external right lanes 1kb GeneRuler DNA 
marker was loaded. 
Figure 7 | Agarose gel electrophoresis of CHQ5B DNA after nuclei crosslinking and sonication.  
Left: 1kb GeneRuler DNA ladder on the first lane and post-sonication CHQ5B Mb DNA on the second lane. 
Right: post-sonication CHQ5B Mt DNA on the first lane, pre-sonication CHQ5B Mt DNA ladder on the 
second and 1kb Gene Ruler DNA marker on the third. 
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Figure 9 | Agarose gel electrophoresis of FOS semiquantitative PCR in Mb TB- and H3K9me3-
immunoprecipitated samples. FOS band becomes visible  both in H3K9me3- and TBP-
immunoprecipitated sample at the 38th PCR cycle. On the external left and external right lanes 1kb 
GeneRuler DNA marker was loaded. 
 
The PCR results were not satisfactory, as it can be seen in Figure 8 and Figure 9.  
Bands were detected only after a high number of PCR cycles and the enrichment 
was equivalent to two PCR cycles only. Nevertheless, considering both the limiting 
amount of template DNA and the limits of the semi-quantitative PCR, we decided to 
prepare the sequencing library to better understand the ChIP experiment. 
SOLiD sequencing 
DNA for sequencing was prepared according to the Mokry’s protocol (Morky M et 
al., 2010), immunoprecipitated DNA was sonicated to produce fragments 150-
250bp in length, which is compatible with SOLiD library preparation. Sequencing 
libraries were prepared following the SOLiD™ manual and sequenced in a lane of 
SOLiD™ 5500xl. As expected, the resulted coverage was low, but enough to make 
some considerations on the experimental results. 
PASS software was used to align the reads on the reference genome and the 
results are reported (Table 2). 
 
Table 2 – Technical data on the SOLiD sequencing of H3K9me3- and TBP- immunoprecipitated DNA 
in CHQ5B Mb and Mt. 
Reads Mb H3K9me3 Mb TBP Mt H3K9me3 Mt H3K9me3 
Total 21.675,623 37,037,894 24,862,470 23,218,274 
Filtered-out 1,806,614 2,929,205 2,012,372 1,946,813 
Aligned 17,506,469 29,360,242 20,208,011 19,357,009 
Aligned/Filtered 81 % 79 % 81 % 83 % 
Unique/Filtered 72 % 71 % 73 % 75 % 
 
 
A quick look at the reads aligned in the genome browser confirmed the results of 
the semiquantitative PCR: there is a high background noise (Figure 10). 
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Figure 10 | Screenshot of the IGV view of ChIP-seq aligned reads. From the top to the bottom the 
samples are: Mt TBP, Mt H3K9me3, Mb TBP and Mb H3K9me3. 
 
This was the first sequenced ChIP-seq experiment in the lab and, in order to learn 
how to manage the data, a test with CLC software was performed to search for 
enriched peaks. The results are reported in the Table 3. 
Table 3 – Matrix of peaks in common among ChIP-seq experiments. For example, 15 peaks were 
found by CLC in the TBP-immunoprecipitated Mb sample; of these peaks 15 were present only in the 
Mb TBP sample, 4 were shared between Mb TBP and Mb H3K9me3, 6 were shared between Mb 
TBP and Mt H3K9me3 and 5 between Mb TBP and Mt TBP. 
 Mb H3K9me3    
Mb H3K9me3 7 (0 unique peaks) Mb TBP   
Mb TBP 4 overlapping peaks 22 (15) Mt H3K9me3  
Mt H3K9me3 5  6 15 (5) Mt TBP 
Mt TBP 4  5 7 16 (7) 
 
 
Normally, ChIP-seq experiments show thousands of enriched regions, instead this 
experiment detected only 7-22 peaks per sample. Even if it is known that low 
coverage can flatten the signal-to-noise ratio thus impairing peaks identification, in 
this case coverage cannot justify the results. Moreover, when considering the 
position of the few peaks in the genome, overlaps between euchromatic- and 
heterochromatic-peaks are observed: as reported in Table 3, TBP- and H3K9me3-
immunoprecipitated samples share 50% of the peaks. In conclusion, 
immunoprecipitation specificity should be improved in future experiments. 
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Native ChIP (nChIP) 
The absence of cross-linking makes native chromatin suitable for studying proteins that are tightly 
associated to the DNA, such as histones. An overview of the experiment is reported in  
Figure 11. 
 
 
Figure 11 | native ChIP outline: after nuclei isolation chromatin is digested with micrococcal nuclase to 
produce fragments suitable for immunoprecipitation. After the immunoprecipitation of DNA-protein 
coplexes of interest, DNA is isolated and sequenced. 
 
 
After micrococcal nuclease digestion of the nuclei, native ChIP was performed on 
1x106 CHQ5B myoblasts, using an antibody against H3K9me3 (2µg) and a normal 
mouse IgG (2µg) as a negative control. This experiment yielded 2ng of 
immunoprecipitated DNA for the H3K9me3 sample and 1ng for negative control. 
Since no standard protocols for sequencing library preparations were available, I 
optimized an Ion PGM™ protocol for Ion Proton™ sequencing. The main difference 
between Ion PGM™ and Proton™ sequencing library preparation is the initial DNA 
fragment size. In the immunoprecipitated sample the DNA is a nucleosome-ladder 
of fragments 150-850bp in length. Micrococcal nuclease digested chromatin (50 
ng) was used to set-up the sonication conditions in order to have a 100-150bp 
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smear, and 2ng of this sheared DNA were used to optimize the low-input Ion 
PGM™ protocol for Ion Proton™ sequencing (Figure 12). 
 
 
Figure 12| Agilent bioanalyzer trace of the Ion Proton sequencing library prepared from 2ng of starting 
DNA. 
 
Nevertheless, the sequencing library preparation using the nChIP-DNA sample was 
critical and adapters were present in the library only at the end of the protocol 
(Figure 13).  
 
 
Figure 13 | Agilent Bioanalyzer trace of the Ion Proton sequencing library prepared from the 2ng of 
H3K9me3 immunoprecipitated DNA sample. Only adapters are visible as high peaks in the left part of 
the trace. 
 
We found the problem to be in the sonication step: in fact, even if the 
immunoprecipitated DNA yields were reproducible between both the technical and 
biological replicas, we could not perform a proper nChIP-seq experiment because 
of the impossibility of efficiently shearing 2ng of DNA (Figure 14). 
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Figure 14| Agilent Bioanalyzer trace of 2ng of microccocal digested DNA after sonication. 
 
For crosslinked chromatin immunoprecipitation, our results suggest that a better 
evaluation of the immunoprecipitation conditions is highly recommended for future 
experiments. For what concern native ChIP, even if the immunoprecipitation 
protocol seems to work, in our hand it was impossible to construct sequencing 
libraries from such a small amount of initial DNA. Therefore we decided to test a 
commercially available kit, which claim to perform ChIP from 100,000 cells. The 
results of this definitive method will be presented and discussed in the “Results and 
discussion” chapter. 
 
 
DNA methylation 
DNA cytosine methylation in CpG dinucleotide context has a significant role in 
downregulating gene expression. One of the aims of this PhD project was to 
investigate the contribution of DNA methylation on differential gene-expression 
profiles observed between Mb and Mt. Transcriptomics analysis was performed in 
the laboratory on CHQ5B Mb and Mt by Rusha Guha, another PhD student, and 
the data are available in her PhD thesis. 
To study DNA methylation we chose a BS-seq approach. Sodium bisulfite DNA 
treatment chemically converts the unmethylated cytosines to uracils, while leaving 
methylated cytosine unaltered; this treatment, together with next generation 
sequencing, offers single-base resolution of methylated sites. To be reliable, the 
conversion should be complete, so that every C sequenced was really methylated 
in the original sample. 
Sodium bisulfite treatment is harsh since it can completely degrade the nucleic acid 
during the conversion step. We encountered this problem when the DNA used for 
the experiment was not sufficiently pure. Therefore the NanoDrop™ 
spectrophotometer was used to assess DNA quality and only samples with 
A260/230 ≥ 2 and A260/280 ≥ 1.8 were used for BS-seq protocol analyses. 
A novel method for studying DNA methylation using the SOLiD™ 5500xl platform 
was conceived and developed in collaboration with Robin Targon, another PhD 
student in Prof. Valle group. The preliminary method is described in this section, the 
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definitive one in the “Results and discussion” section. In order to improve the time 
taken for BS-seq, Ion Proton™ platform was also tested for DNA methylation 
analysis. 
Methylome SOLiD™ sequencing preliminary protocol (MeSS v1) 
Next generation sequencing of the whole human methylome at single base 
resolution is expensive and the data analysis is tricky, due to the reduced 
complexity of bisulfite-converted genome. In fact, after bisulfite conversion, the two 
DNA original strands are no more complementary, and the same is for the reverse 
complementary of converted strands (Figure 15). 
 
 
Figure 15 | Effects of sodium bisulfite DNA treatment. After bisulfite conversion the two strands of DNA 
are no more complementary and the complexity of the genome is highly reduced. 
The alignment of sequencing reads on an in silico bisulfite-converted reference 
genome is a challenging bioinformatics task. To facilitate data analyses, researchers 
are now producing strand-specific BS-seq libraries by the use of methylated 
adapters, but the method is costly and time-consuming. In collaboration with Robin 
Targon we conceived a novel approach to produce strand-specific libraries for BS-
seq on the SOLiD™ platform. The method should be easily adapted to every type 
of NGS platform. In this section I report the results of the preliminary protocol for 
methylome SOLiD™ sequencing (MeSS), while the results of the definitive protocol 
will be discussed in the Results chapter. 
MeSS v1 was designed to be a fast and cheap single-tube protocol for constructing 
BS-seq strand-specific libraries; it was conceived to perform with 50ng initial DNA 
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and to avoid intermediate purifications and buffer exchanges. The method is based 
on the hybridization of protruding adapters suitable for SOLiD sequencing on 
bisulfite-converted, sheared and single-stranded DNA (Figure 16). These protruding 
adapters are designed to hybridize the DNA in a unique direction so that, after PCR 
library amplification, only the original bisulfite converted DNA strand would be 
sequenced. Only 10 cycles of PCR amplification were required to obtain the 
sequencing library, and this should have reduced read clonality, another advantage 
of using MeSS. 
MeSS v1 protocol was applied to 50ng of CHQ5B Mb DNA, and the sample was 
initially sequenced in one lane of SOLiD™ 5500xl platform. The produced number 
of reads was slightly under the average output for SOLiD sequencing, with 110M 
reads of output instead of 120M. Data analysis was performed with the PASS-bis 
software and only 11M reads were assignable unambiguously to the human 
genome; of these unique reads, 7M were identical and mapped uniquely on the 
subtelomeric region of Chr10. We analysed this sequence, but we were not able to 
define its origin and we decided not to investigate further and proceed with the 
analysis of the remaining reads. On the 4M of unique and non-repeated reads 
mapping on the genome we assessed a percentage of directionality that was higher 
than 90%.  
The high percentage of non-mapping reads suggested that further optimization of 
the MeSS technique was required, and we came out with MeSS v2 protocol, 
whose success and results will be discussed later in this thesis. 
 
 
Figure 16| MeSS v1 workflow and results: the hybridization of protruding adapters on bisulfite treated 
DNA allow to construct strand-specific seqeuncing libraries. 
Methylome Proton Sequencing 
The sequencing rapidity of Ion Proton™ is unmatched and, in order to investigate 
its performance in methylation studies, we performed a BS-seq test without 
checking directionality (Figure 17). Double-stranded DNA was obtained by DNA 
polymerase I-extension of random hexamers on the bisulfite-treated single-stranded 
DNA and the sequencing library was prepared following standard protocol. 
In our hands Ion Proton™ did not seem to work perfectly with BS-seq: sequencing 
output was 1.1Gb with an average read length of 35bp, standard Ion Proton™ 
output >10Gb with a 120bp the read-length. 
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Fig. 3 | MeSS workflow: protruding adapters permit the construction of a strand-specific library for BS-seq 
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Figure 17 | Outline of the Ion Proton BS-seq protocol. 
 
It is known that Ion-Proton does not perform very well on homopolymeric stretches. 
Therefore we hypothesize that the increased number of homopolymeric stretches 
derived from bisulfite treatment impaired the Ion Proton™ sequencing. Nevertheless 
we did not prove this hypothesis and developed the definitive protocol for 
Methylome SOLiD™ sequencing. 
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Results and discussion 
Is DNA methylation involved in myogenesis? 
MeSS v2 for whole-methylome: an expensive gold-standard! 
Easy, innovative, exhaustive...but still too expensive 
Sodium bisulfite treatment converts all unmethylated cytosines of the DNA into 
uracils, while leaving methylated C unaltered. This allows the genome-wide study of 
DNA methylation at single-base resolution. 
At the beginning of this project only few methods were available for studying whole-
genome DNA methylation, all being very expensive and requiring huge amount of 
starting DNA. In order to simplify bioinformatics analysis, the available techniques 
use methylated adapters to construct strand-specific sequencing libraries before 
sodium bisulfite DNA treatment. Sodium bisulfite typically degrades 80-90% of the 
starting DNA during conversion. Because of this degradation, the initial amount of 
DNA is 2-4µg, and many pre-amplification PCR cycles are required for sequencing. 
Moreover, when di-tagged DNA sequencing libraries are treated with sodium 
bisulfite, the vast majority of fragments will be broken, resulting in mono-tagged 
fragments that impair enrichment and sequencing results. 
In order to optimize DNA methylation analysis, in collaboration with Robin Targon 
who is another PhD student, we developed a novel approach in which bisulfite 
conversion is performed before library preparation. This method, that we call MeSS 
v2, is rapid and cost-effective, and notably reduced the required starting amount of 
DNA. In particular, we used 300ng of NanoDrop-quantified DNA to successfully 
carry out the protocol that requires only one intermediate purification step. Last 
September, as we were analysing the first MeSS v2 results, Khanna A et al. 
(Epicentre® company - Nat. Methods, 2013) published a very similar method. 
Technical details of MeSS v2 protocol 
300ng of Nanodrop-quantified Mb DNA were sonicated and then bisulfite treated: 
after considering the degradation that follows bisulfite treatment we found the right 
DNA sonication conditions (Figure 18).  
 
Figure 18 | Agilent profile of the sonicated and bisulfite-treated Mb DNA used for MeSS v2 protocol. 
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At first, the annealing of a 3’-blocked single-stranded adapter followed by a 
template-switching reaction produced the mono-tagged DNA fragment (with the 
sequencing tag at the 3’ end of the DNA). Then, after the ligation of the second 
adapter at the 5’ end, 15 PCR cycles produced the sequencing library for SOLiD 
5500xl platform (Figure 19). 
 
Figure 19 | MeSS v2 library constructed from 300ng of Mb DNA. 
 
 
MeSS v2 protocol is summarized in Figure 20. 
 
 
Figure 20| MeSS v2 outline 
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Data analysis was performed using the analysis pipeline based on Pass-bis 
software. In Table 4 the technical aspects of the sequencing trial lane are reported. 
 
Table 4 – Technical aspects of MeSS v2 protocol 
tota l number of reads 104M 
mapping eff ic iency 60% 
unique > 80% of the mapped 
direct ional i ty > 90% 
 
The whole-methylome analysis of one Mb sample required the sequencing of 12 
SOLiD lanes, in order to obtain realistic methylation levels. Bioinformatics analyses 
are ongoing, but preliminary results obtained by comparing MeSS with SureSelect 
method (discussed below) show that the methylation levels are comparable in the 
shared regions. Further investigation is required for mapping all CG, CHG, CHH 
methylation positions along the genome, in order to evaluate the existence of 
methylation patterns, the presence of extra-CpG methylation in muscle, the role of 
CHG and CHH in myogenesis. 
The method we propose allows the investigation of cytosine methylation at single 
base resolution in CG, CHG and CHH contexts, as other methods do, but with the 
advantage of saving DNA and time. The problem of all kinds of human whole-
methylome analysis is the cost, which is around 10,000$ for obtaining 20X 
coverage of the genome, therefore we decided not to investigate the role of DNA 
methylation in adult myogenesis with the whole-genome approach. Although, the 
working protocol we conceived is now available in the laboratory and can be used, 
for example, for studying the methylome of smaller genomes, or as an alternative to 
RRBS after enzymatic digestion of DNA.  
In conclusion, we developed a method for methylome studies that can compete 
with the recent published epicentre kit, with the advantage for MeSS to be publicly 
available and easily customizable for every sequencing platform, by simple changing 
the adapters sequences. 
 
SureSelect Methyl-Seq Target enrichment 
A valid alternative to whole-methylome BS-seq 
One of the objectives of my research was to study the effects of methylation on the 
differentiation process in human muscle, from myoblasts to myotubes. To do this I 
tested an enrichment kit, the SureSelect Human MethylSeq target enrichment kit 
(Agilent). This kit is designed to selectively capture by hybridization 84Mbp of the 
human genome; in particular, it captures regions containing 3.7M CpG sites mainly 
in CpG islands, shores and shelves, and in gene promoters and enhancers. Since 
methylation of these regions impairs gene transcription, this method can be used to 
obtain preliminary, but highly informative data on the role of CpG methylation in 
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adult myogenesis. It also has the added advantage of being quicker and cheaper 
than performing whole genome sequencing. The DNA methylation data obtained 
with the kit could be integrated with the ChIP-seq and also with the transcriptomic 
data produced in the lab by Rusha Guha, another PhD student working in the 
laboratory. 
The SureSelect Human MethylSeq kit was successfully used for the enrichment of 2 
Mb 2 Mt samples before bisulfite conversion with the procedure illustrated in Figure 
21. Briefly, methylated adapters are ligated to sonicated DNA before capturing CpG 
rich regions with biotinylated RNA probes. Then, captured DNA was isolated and 
bisulfite treated before PCR amplification. All the libraries were sequenced as 
paired-end on an Illumina HiSeq1000 platform and the data were analysed with 
Pass-bis software. 
 
Figure 21 | Outline of SureSelect MethylSeq Target enrichment kit.  
At the time we bought the kit there was no literature on it, therefore we had to 
validate its technical performance before analysing the sequencing data. 
Kit performance: technical validation 
To test the performance of the kit the percentage of in-target reads and of regions 
that are effectively captured, as well as the average coverage were calculated. 
Mapping efficiency was very high (Figure 22) and more than 85% of the reads were 
found to be in-target and more than 90% of the regions that were supposed to be 
captured were actually captured with an average coverage of at least, 20X.  
 
Figure 22 | Mapping efficiency of SureSelct sequenced reads: 1= mapped reads, 2= unmapped reads. 
The vast majority of reads has been mapped. 
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These data confirmed the SureSelect kit to be a valid alternative to RRBS: both the 
methods has the disadvantage of bisulfite treatment after library construction and 
necessitate a huge amount (µg) of starting DNA. Compared to RRBS the 
SureSelect kit had the advantage that no enzymatic digestion and gel excision were 
required. In the literature RRBS is cited (Stirzaker C et al., 2014) to capture less 
than 5000, 000 CpG sites, whereas the SureSelect kit method captured at least 
2,700,000. 
Differentially methylated regions and sites 
After sequencing the four samples (2Mb and 2Mt) the Pass-bis software was then 
used to map the reads for methylation calling after pairing. Methylation data were 
used as input for an R methyl kit (Akalin A et al., 2012), which calculated both 
differentially, methylated sites (DMS) and regions (DMR). 
There was very little difference in DNA methylation between Mb and Mt. In fact 
there are 577 DMS between Mb and Mt samples, located near 442 genes. In a 
recently published paper Tsumagari K et al. (Tsumagari K et al. 2013) concluded 
that DNA methylation only has a minor role in regulating adult myogenesis, being 
more a consequence than the cause of altered gene expression during the 
differentiation of Mb into Mt.  
Nevertheless, we checked for DNA methylation changes in regions, instead of 
single sites, by adopting a 100bp window sliding every 10bp along the genome. R-
methyl kit detected 1,917different DMR between Mb and Mt, near 1,404 genes. In 
particular 1,019 DMR were hypermethylated and 385 hypomethylated in Mt 
compared to Mb. 
The comparison between DMR and differentially expressed gene (DEG) data are 
summarized in Table 5. 
 
Table 5 – Classification of DMRs. The two rows (hypometylated and hypermethylated DMRs) have 
compared with gene expression profiling of Mt vs Mb cells. 
 
DMR 
no change 
in gene expr. 
overexpressed in 
Mt compared to 
Mb 
underexpressed 
in Mt compared 
to Mb 
very low 
expression 
ncRNA 
genes 
Hypomethylated 
(385) 201 38 14 132 60 
Hypermethylated 
(1,019) 397 77 80 465 204 
 
After obtaining ChIP-seq results (see next paragraph) I observed that, among the 
DMR, which do not have a correspondently expressed gene, there is a high 
percentage of genes with H3K27me3, therefore I thought that hypermethylated 
regions may be already heterochromatic or that the process of 
heterochromatinization had already started before DNA methylation. From the ChIP-
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seq results I hope to see if hypomethylation results in chromatin activation of 
miRNA. 
Analysis of results 
DMR, DMS and gene expression data were analysed both for the Kegg pathway 
and Gene ontology (Table 6 and Table 7). 
Table 6 | DAVID Gene ontology: molecular function results with associated p-values 
DEG (1074/2255 DAVID IDs) DMR (572/118 DAVID IDs) DMS (122/365 DAVID 
IDs) 
cytoskeletal protein binding (2.6E-
16) 
sequence-specific DNA binding (1.9E-
7) 
transcription regulator 
activity (1.4E-4) 
structural constituent of muscle 
(2.8E-15) 
Ras guanyl-nucleotide exchange 
factor activity (8.7E-7) 
transcription factor activity 
(1.7E-4) 
actin binding (3.7E-12) Rho guanyl-nucleotide exchange 
factor activity (6.2E-6) 
sequence-specific DNA 
binding (3.9E-4) 
 
 
Table 7 | Gene ontology: biological pathway results for the first five muscle-related pathways with 
associated p-value. 
DEG (1408/2255 DAVID 
IDs) 
DMR (587/118 DAVID IDs) DMS (182/365 DAVID IDs) 
muscle system process (5.4E-21) embryonic skeletal muscle 
development (3.8E-7) 
heart development (1.3E-3) 
muscle contraction (8.7E-21) skeletal system morphogenesis 
(2.1E-6) 
heart morphogenesis (3.3E-3) 
cytoskeleton organization (2.0E-
20) 
skeletal system development (2.1E-
6) 
regulation of skeletal muscle 
tissue development (1.7E-2) 
muscle organ development 
(2.2E-18) 
embryonic skeletal system 
morphogenesis (2.1E-5) 
regulation of muscle 
development (1.9E-2) 
muscle tissue development 
(4.2E-11) 
heart development (4.2E-3) cytoskeleton organization (2.9E-
2) 
 
DMR and DMS KEGG pathway results do not highlight any pathways specific for 
myogenesis, even if there are pathways for cell-cell junctions, for cancer and Wnt 
and MAPK signalling pathways. 
In the KEGG pathways obtained from gene expression data, as expected the cell 
cycle and DNA replication appear to be inhibited during the differentiation of Mb to 
Mt, however muscle-related pathways are activated, as well as DNA repair 
mechanisms. Taken together, the gene ontology and Kegg pathways show the 
expression of muscle specific genes during differentiation, as structural components 
of the sarcomere and machinery for muscle contraction. Moreover although the cell 
cycle is inhibited during differentiation, the DNA repair mechanisms still remain 
active in the form of mismatch, base excision and nucleotide excision repair. 
On the other hand, DNA methylation is linked to pathways that are more likely 
related to DNA-binding activities rather than muscle-specific genes. Even if gene 
ontology detected a significant number of terms associated with muscle 
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development, the significance is less than that of same terms in gene expression 
data. 
Our results suggest that the involvement of DNA methylation during Mb 
differentiation to Mt does not show a direct, predominant role and, as Tsumagari 
(Tsumagari K et al, 2013) suggested, the demethylation observed between Mb-Mt 
and adult skeletal muscle seem to be more likely a consequence of altered gene 
expression, rather than the cause. Further investigation is required to clarify the role 
of DNA methylation during myogenesis, which is far from being completely 
understood. The presence of DMR in non-coding genes leads me to formulate a 
novel hypothesis on the epigenetic events during myogenesis.  
Epigenetic mechanisms in addition to- or other than DNA methylation are certainly 
involved in activating muscle-specific genes and in repressing the cell cycle and, in 
particular, we hypothesise a role for histone modification complexes, DNA 
hydroxymethylation and regulatory RNAs. At first, chromatin compaction impairs 
gene activity by preventing the access of transcription factors to the promoters: 
MyoD itself recruits histone acetylases on muscle-specific gene promoters, thus 
enhancing the formation of euchromatin.  
Moreover, we observed that many DMR map near non-coding RNA genes, so it 
would be interesting to investigate the link between methylation levels, gene 
expression and biological function of the variety of miRNA, miscRNA, lincRNA 
regions that emerge from our data. 
Eventually, as recent literature suggests, we can hypothesise a role for DNA 
hydroxymethylation in activating methylated promoters: on the one side, if 
hydroxymethylation is involved in muscle differentiation, this could explain, at least in 
part, the small number of observed DMR. Supporting this hypothesis, we observed 
the expression of TET1 and the activation of DNA excision repair pathways, which 
can demethylate the DNA to the hypomethylated state described in adult skeletal 
muscle by Tsumagari K et al. (Tsumagari K et al., 2013). 
In order to start unravelling the epigenetic mechanisms other than DNA methylation 
in myogenesis, I focused on chromatin state, thus setting-up chromatin 
immunoprecipitation. In conclusion I think it would be worthwhile to correlate 
histone modifications, DNA methylation and gene expression data. 
 
ChIP-seq 
ChIP-seq was performed on 100,000 Mb cells for each antibody and 
immunoprecipitated DNA was sequenced on the SOLiD 5500xl platform. For 
studying gene activity we chose 2 euchromatic markers (H3K4me3 and H3K9ac) 
and an heterochromatin marker (H3K27me3). 
Trypsinized Mb were crosslinked in solution, and then sonicated to fragment 
chromatin in 100-250bp long DNA fragments; chromatin was then 
immunoprecipitated and the immunoprecipitated DNA was used for preparing a 
fragment sequencing library. 
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Read alignment and mapping 
After sequencing, reads were aligned using Pass software, and only uniquely 
mapped reads were used for peak-calling and annotation using commercial CLC 
software for peak calling.  
In particular, CLC analysis identified 2,201 peaks for H3K4me3 (assigned to 1,996 
genes), and 1,608 peaks for H3K9ac (assigned to 1486 genes). An example is 
shown in Figure 23. 
 
 
Figure 23| IGV view of the ChIP-seq profile of the transcription start site of MYBL1, an actively 
transcribed gene in Mb. From top to bottom, the four alignement tracks from ChIP-seq experiment 
are: H3K4me3 (euchromatin marker), H3K9ac (euchromatin marker), H3K27me3 (heterochromatin 
marker), and normal rabbit IgG (control). 
 
We observed an impressive concordance between ChIP-seq and gene expression 
data and, in fact more than 80% of the peaks assigned to effectively transcribed 
genes. 14% of the peaks mapped in the TSS of novel non-coding RNAs (miRNA, 
lincRNA, miscRNA, that show very low expression in transcriptomic analysis). There 
are some possible explanations for this event: on the one hand, these RNAs might 
be expressed at very low level and the normalization of RNA-seq data masks their 
presence. On the other hand, since these non-coding genes are classified as 
“novel” they might be absent in the annotation system used for gene expression 
data. If the second hypothesis is true, the update of the annotation can solve the 
situation. Of course, the presence of H3K4me3 and H3K9ac on non-coding RNAs 
open a fascinating scenario on the epigenetic role of these transcripts in 
myogenesis, especially if considering the findings about DMRs in miRNA, miscRNA, 
snRNA and lincRNA genes. 
Less than 2% of the euchromatin peaks co-localized with H3K27me3 and the 
presence of the heterochromatin marker can be, at least in part, the reason why the 
genes are very poorly expressed. An example is repored in Figure 24. 
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Figure 24 | IGV view of the ChIP-seq profile of the transcription start site of ZSWIM5, a gene non 
transcribed in Mb. From top to bottom, the four alignement tracks from ChIP-seq experiment are: 
H3K4me3 (euchromatin marker), H3K9ac (euchromatin marker), H3K27me3 (heterochromatin marker), 
and normal rabbit IgG (control). 
Less than 2% of euchromatin peaks are probably mis-assigned: in fact, these 
genes are very close to other genes, which are expressed.  
Finally, about 2% of the peaks show both the euchromatin markers, but they are 
not transcribed. 
After correlating ChIP-seq data with gene expression and DNA methylation data in 
Mb I am now producing the ChIP-seq data for Mt in order to define the existence of 
chromatin dynamics in controlling myogenesis. 
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Conclusions 
The activation or repression of genes that control adult myogenesis requires an 
extensive crosstalk between transcription factors and epigenetics players, such as 
DNA methylation and histone modifications. The final goal of my PhD project is the 
description of the epigenetic mechanisms underlying human muscle differentiation.  
When I started this PhD project, epigenetics was still an innovative field and I had to 
deal with the lack of tools for studying epigenetic mechanisms. Therefore, as a first 
task of my project, I set-up tools for investigating DNA methylation and protein-DNA 
interactions at high resolution, by the use of next generation sequencing 
technologies. In particular, I set-up BS-seq and ChIP-seq protocols. 
 
The gold standard technique for DNA methylation studies is BS-seq (bisulfite 
treatment of DNA followed by deep sequencing), in which bisulfite converts all the 
unmethylated cytosines to uracils and leaves methylated ones unaltered, thus 
permitting single-base resolution. Next generation sequencing of the whole human 
methylome at single base resolution is expensive and the data analysis is 
challenging, due to the reduced complexity of bisulfite-converted genome. We 
developed a novel method, that we called MeSS (Methylome SOLiD Sequencing), 
to investigate whole-genome methylation. The approach and performance of this 
new method are similar to the ones recently proposed by the commercially available 
Epicentre® kit (Nat. Methods, 2013). The approach we propose relies on post-
bisulfite library construction that avoids the degradation of the library during the 
conversion step and increases sequencing efficiency. Moreover, MeSS protocol 
permits the construction of strand-specific libraries from only 300ng of starting 
DNA. We used MeSS to produce the whole methylome of one myoblast sample. 
Since we were interested in evaluating the involvement of DNA methylation in 
myogenesis, the whole-methylome analysis of myoblast and myotube samples was 
challenging and demanding. Therefore we opted for analysing only a subset of 
genomic regions using the Agilent SureSelect Methyl Seq Enrichment kit, which 
claims to capture by hybridization 3.7M CpG sites in gene promoters, CpG islands, 
shelves and shores. Since there were not published results obtained with this 
SureSelect kit, before analysing the data we evaluated the performance of the kit 
and we found that more than 2.7M CpG sites are effectively captured with a 
minimum coverage of 10X. Moreover we calculated that more than 85% of the 
reads were in-target and, among the regions that should be captured by the kit, 
more than 90% have an average coverage of at least 5X. 
Since the positive results of the performance evaluation of the SureSelect kit, we 
successfully used it to determine the differentially methylated sites (DMS) and 
regions (DMR) between myoblasts and myotubes. 577 DMS and 1917 DMR were 
found between the two conditions and more than half of these sites did not show 
correlation with gene expression. Moreover, the significativity of muscle-related 
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terms in Gene Ontology is lower than the one emerging from RNA-seq data. 
Therefore we hypothesized that the DNA methylation role in myogenesis is not 
predominant, at least in the activation of muscle-specific genes during 
differentiation. However, many differentially methylated regions or sites were 
associated to genes coding for regulatory RNAs and, as a future perspective, a 
correlation between DNA methylation and expression level of corresponding 
regulatory RNAs should be further investigated.  
 
Since chromatin compaction has an important role in regulating the accessibility of 
transcriptional machinery to the DNA, and we are interested in describing the 
epigenetic landscape of myogenesis, ChIP-seq was set-up in parallel with BS-seq. 
I focused on ChIP-seq experiments to define the localization of H3K9ac, H3K4me3 
and H3K27me3 histone modifications on DNA. A homemade method for 
crosslinked-ChIP (X-ChIP) has been widely tested and immunoprecipitation was 
performed both on myoblast and myotubes. Analysis of the sequencing results 
suggested that a careful evaluation of the immunoprecipitation conditions is highly 
recommended. 
Native ChIP was also tested, and, in order to prepare sequencing libraries from less 
than 2ng of starting DNA, I adapted an Ion PGM protocol to the Ion Proton 
platform, but the low recovery of immunoprecipitated DNA (2ng) and the need for 
sonicating this DNA made the nChIP library preparation very problematic. 
At the end, the True MicroChIP kit from Diagenode was used for 
immunoprecipitation experiments on myoblasts using two euchromatin markers 
(H3K9ac and H3K4me3) and an heterochromatin one (H3K27me3). By comparing 
ChIP-seq with RNA-seq data, we observed that more than 80% of H3K9ac and 
H3K4ac peaks are localized in the transcription start site of actively transcribed 
genes and H3K27me3 was found in transcriptionally inactive regions, as expected. 
An interesting finding was the localization of euchromatin-associated peaks in the 
TSS of novel non-coding RNAs. In the immediate future we are planning to perform 
the ChIP-seq of myotubes for mapping the same histone modifications. This will 
allow us to have an exhaustive view of the chromatin state during myogenic 
differentiation. 
As I began the integration of BS-seq, ChIP-seq and gene expression data I noticed 
that both in Kegg pathway and Gene Ontology, excision repair mechanism and 
TET1 are active during differentiation. Considering that Tsumagari K et al. (2013) 
found high levels of cytosine hydroxymethylation in the promoter of muscle specific 
genes, the hypothesis of a role of hydroxymethylation in myogenesis would be one 
of our future priorities to investigate. 
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